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Abstract
The xenoestrogen diethylstilbestrol (DES) is commonly believed to mimic the action of the natural estrogen 17β-
estradiol (E2). To determine if these two estrogens exert similar actions in prostate carcinogenesis, we elevated
circulating levels of estrogen in Noble (NBL) rats with E2/DES–filled implants, while maintaining physiological levels
of testosterone (T) in the animals with T-filled implants. The two estrogens induced dysplasia in a lobe-specific
manner, with E2 targeting only the lateral prostate (LP) and DES impacting only the ventral prostate (VP). Gene
expression profiling identified distinct and common E2-disrupted versus DES-disrupted gene networks in each
lobe. More importantly, hierarchical clustering analyses revealed that T + E2 treatment primarily affected the gene
expression pattern in the LP, whereas T + DES treatment primarily affected the gene expression profile in the VP.
Gene ontology analyses and pathway mapping suggest that the two hormone treatments disrupt unique and/or
common cellular processes, including cell development, proliferation, motility, apoptosis, and estrogen signaling,
which may be linked to dysplasia development in the rat prostate. These findings suggest that the effects of
xenoestrogens and natural estrogens on the rat prostate are more divergent than previously suspected and that
these differences may explain the lobe-specific carcinogenic actions of the hormones.
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Introduction
Androgens are essential to the growth and functioning of the normal
prostate and undoubtedly play a key role in prostate carcinogenesis
[1]. Emerging evidence shows that estrogens also have a critical role
in prostatic diseases, including prostate cancer (PCa) [2,3]. The in-
cidence of PCa increases dramatically with age in human males,
whose testosterone (T) levels in both the circulation and in prostate
decline, whereas those of 17β-estradiol (E2) remain relatively stable
[2–4]. Thus, the age-associated alterations in the sex hormone milieu
toward an estrogen predominance have been proposed as an endoge-
nous risk factor for prostate carcinogenesis. Dynamic changes in the
expression of estrogen receptor-β during PCa progression in humans
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[5,6] also suggest the involvement of estrogen signaling in the ma-
lignant transformation of the prostate. Moreover, the findings of ab-
errant activation of aromatase expression in benign prostatic
hyperplasia and PCa [3,7] further advance the concept that local pro-
duction of estrogens is pivotal in the pathobiology of this gland.
Humans are exposed to xenoestrogens from various sources, in-
cluding food, drugs, and other exogenous venues. Xenoestrogens
are believed to cause endocrine disruptions that lead to pathogenesis
in reproductive end organs [8,9]. One agent of public health concern
is diethylstilbestrol (DES), a synthetic estrogen, which was widely
used as a growth-promoting animal feed additive [10]. Epidemiolog-
ical studies have established a strong association between maternal
exposure to DES and increased risk of vaginal, cervical, and perhaps
breast cancers in DES daughters [11,12]. It remains uncertain, how-
ever, whether prenatal exposure to DES elevates cancer risk in men
[13]. Transient exposure of neonatal rodents to estrogen increases
susceptibility of the prostate to inflammation and cancer develop-
ment later in life [14]. Together, these findings strongly suggest that
natural or synthetic estrogen–mediated endocrine disruption leads to
the evolution of prostatic diseases, including PCa.
We have established the T plus estrogen–induced dysplasia/
carcinoma model in Noble (NBL) rats as a robust study system for
deciphering the contributions of estrogens, in adulthood, on the
pathogenesis of dysplasia, a precancerous lesion, and adenocarcinoma
of the prostate [15,16]. In this model, estrogens are administered
through subcutaneous implants of hormone-filled Silastic capsules
with the coimplantation of T-filled capsules to maintain physiological
levels of this androgen in the circulation [17]. It is well known that
increased exposure to estrogens leads to a decline in circulating levels
of T through the hypothalamic–pituitary–gonadal axis. The topograph-
ical localization of premalignant/malignant lesions within the rat pros-
tate gland has been found to be dependent on the type of estrogens
used. Under the same exogenous androgen support, E2 induces epithe-
lial dysplasia and adenocarcinoma in the lateral prostate (LP) but not in
the ventral prostate (VP) [16–19], whereas synthetic DES specifically
targets the VP but not the LP [19,20]. Why two different estrogens
induce lobe-specific carcinogenic actions in the prostate remains un-
clear. To address this issue, we conducted gene expression profiling
analyses on the LP and VP of NBL rats exposed to T + E2 or T +
DES. The experimental design and the application of a bioinformatic
tool of gene network mapping enabled us to identify lobe-specific and
common estrogen–mediated disruptions in multiple biologic networks/
pathways that may be linked to prostate carcinogenesis and explain the
distinctive action of the two estrogens.
Materials and Methods
Animals and Hormonal Treatment
The animal usage protocol was approved by the Institutional An-
imal Care Committee at the University of Cincinnati. Male NBL rats
(5–6 weeks old) were purchased from Charles River Laboratories
(Kingston, NY), kept under standard conditions, and treated as pre-
viously reported [16,19,20]. Briefly, animals were randomized into
three groups (n = 5 for each group). Rats in the T + E2 treatment
group received subcutaneous implants of two pieces of 2-cm-long Si-
lastic capsules containing T (Sigma, St Louis, MO) and one piece of
1-cm-long capsules packed with E2 (Sigma), whereas the T + DES
treatment group received the same number of Silastic capsules of the
same length filled with T and DES (Sigma). Age-matched untreated
control rats were implanted with empty capsules. At the end of a
16-week treatment period, animals were sacrificed with an overdose
of isoflurane, and VPs and LPs were excised. One half of each lobe
was processed for histologic examination, and the other half was
snap-frozen for RNA extraction.
Microarray Hybridization
The Atlas Glass Rat 3.8 I Microarray (Clontech, Palo Alto, CA)
carrying 3800 named rat genes (spotted oligonucleotides) were used
as the gene chip platform. The Atlas Glass Fluorescent Labeling Kit
(Clontech) was used for synthesizing and purifying fluorescent-
labeled cDNA probes for hybridization to glass microarrays. The
labeling and hybridization procedures were performed in accor-
dance with the manufacturer’s instruction manual. In brief, amino-
modified first-strand cDNA probes were synthesized with aminoallyl–
2′-deoxyuridine 5′-triphosphate incorporation. Then Cy3 fluorescent
dye was coupled to the cDNAs derived from individual prostatic
lobes, whereas Cy5 dye was conjugated to the universal rat reference
RNA obtained from Stratagene (La Jolla, CA). Equal quantities
of two labeled probes were mixed and hybridized in a Corning mi-
croarray hybridization chamber (Corning, Corning, NY) at 50°C
overnight (≥16 hours). Spikes of positive control probes were also
included as an internal control for the process of cDNA probe syn-
thesis and the dye-coupled reaction. Finally, the signal was obtained
using a microarray scanner (GenePix 4000B; Axon Instruments, Foster
City, CA). A probe coverage of >90% was achieved for all arrays. Five
animal replicates for each treatment/tissue group (T + E2–treated VP
or LP, T + DES–treated VP and LP, and untreated VP and LP) were
used to conduct a 30-microarray analysis to assess changes in the gene
expression pattern due to treatment and lobe specificity.
Microarray Data Normalization and Analysis
The data were analyzed to identify differentially expressed genes in
1) the T + E2–treated LPs and VPs compared with untreated controls
and 2) the T + DES–treated LPs and VPs compared with untreated
controls. Five biologic replicate arrays for each experimental condi-
tion, all versus universal reference, were performed. R statistical soft-
ware and the limma Bioconductor package [21] were used for
analysis. Data normalization was performed in two steps separately
for each microarray [22–24]. First, background-adjusted intensities
were log-transformed, and the differences (M ) and averages (A) of
log-transformed values were calculated as M = log2(X1) − log2(X2)
and A = [log2(X1) + log2(X2)]/2, where X1 and X2 denote the Cy5
and Cy3 intensities, respectively. Second, normalization was per-
formed by fitting the array-specific local regression model of M as
a function of A and obtaining residuals. The statistical analysis was
performed for each gene separately by fitting a one-way analysis of
variance (ANOVA) model with treatment. Estimated fold changes
were calculated from the ANOVA model; an intensity-based empir-
ical Bayes method was used to modify the resulting t-statistics from
each comparison [25]. This method obtains more precise estimates
of variance by pooling information across genes and by accounting
for the dependency of variance on probe intensity level. Genes with
a false discovery rate (FDR) <0.05 [26] were considered to be sig-
nificantly differentially expressed. Clustering was performed using
normalized, centered sample ratios. The gene list used for clustering
consisted of all genes having an FDR <0.05 for at least one compar-
ison (1063 genes). T + E2 and T + DES samples were each clustered
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using the Ward clustering method and Euclidean dissimilarity metric
with 1063 genes.
Identification of Estrogen-Regulated Gene Expression
Genes differentially regulated in the different lobes with T + DES and
T + E2 treatment were identified separately in each drug treatment. Gene
lists were generated according to their expression signature in different
gene expression clusters; each group was described in the Results section.
Pathway and Network Analysis
Biologic relationships between differentially expressed genes were
mapped by Ingenuity Pathway Analysis (IPA) 3.1 software (www.
ingenuity.com). Gene lists of different patterns of gene expression in
response to T + E2 and T + DES treatments (as described in the
Results section) were uploaded to the IPAWeb application in an Ex-
cel file format containing expression data and GenBank accession
number as identifier. The biologic relationship of uploaded genes
was mapped with IPA software into networks according to the pub-
lished literature in the database. A score was assigned to each net-
work in the data set to estimate the relevance of the network to
the uploaded gene list. A higher score means that the network is
more relevant to the gene list entered by the user [27]. The two
highest score networks were selected in this study, and genes in these
two networks were selected for further post hoc analysis.
Figure 1. Hierarchical clustering analysis of T + E2 and T + DES gene expression data set. (A) Dendrogram of T + E2 expression data set in
LP and VP. (B) Dendrogram of T + DES expression data set in LP and VP. (C) Venn diagram showing the number of genes differentially
expressed in each treatment group compared with the respective untreated control. (D) Gene interaction network of a subset of differen-
tially expressed genes that are common in both LP and VP dysplasia. Genes bordered with red were validated by quantitative real-time PCR.
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Table 1. T + E2–Induced LP Dysplasia Panel: Genes Whose Expression Selectively Changed following T + E2 Treatment in the LPs Harboring Dysplasia, but not in the VPs.
Gene Names Locus ID Symbol Fold Changes Functions
prohibitin* 25344 PHB 3.42 Cell death; cell signaling; cellular growth and proliferation; gene transcription
nuclease-sensitive element binding protein 1* 29206 NSEP1 3.08 Cell death; gene transcription
potassium channel, subfamily K, member 9* 84429 KCNK9 3.08 Cell death
vesicle-associated membrane protein 2* 24803 VAMP2 2.97 Cell death; cellular assembly and organization; cellular movement
cytochrome c oxidase subunit IV isoform 1* 29445 COX4I1 2.71 Others/unclassified
PR-Vbeta1* 498341 PR-Vbeta1 2.68 Others/unclassified
melanocortin 5 receptor* 25726 MC5R 2.47 Cell signaling
glutamate receptor, ionotropic, kainate 3* 298521 GRIK3 2.45 Cell signaling
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4* 54283 PFKFB4 2.41 Others/unclassified
potassium voltage–gated channel, Shaw-related
subfamily, member 1*
25327 KCNC1 2.39 Molecular transport
actin alpha cardiac 1* 29275 ACTC1 2.34 Others/unclassified
eukaryotic translation elongation factor 1 alpha 1* 171361 EEF1A1 2.31 Cell death, protein synthesis
ATPase, Na+/K+ transporting, alpha 3 polypeptide* 24213 ATP1A3 2.29 Inflammation; molecular transport
gamma-aminobutyric acid A receptor, rho 1* 29694 GABRR1 2.25 Cell death; cell signaling
guanylate cyclase 1, soluble, alpha 3* 25201 GUCY1A3 2.25 Cellular movement
transforming growth factor alpha* 24827 TGFA 2.24 Biomolecule metabolism; cell cycle; cell death; cell morphology; cell signaling;
cellular development; cellular growth and proliferation; cellular movement;
gene transcription; molecular transport; protein synthesis
ribosomal protein S12* 65139 RPS12 2.20 Protein synthesis
tumor protein p53* 24842 TP53 2.16 Cell cycle; cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular development; cellular growth and proliferation; cellular
movement; cellular response to therapeutics; DNA replication, recombination
and repair; free radical scavenging; gene transcription; inflammation; molecular
transport; post–translational modification; protein synthesis; RNA
post–transcriptional modification
nuclear receptor subfamily 3, group C,
member 2*
25672 NR3C2 2.13 Biomolecule metabolism; cell signaling; gene transcription; molecular transport;
protein synthesis
secretory carrier membrane protein 1* 29521 SCAMP1 2.09 Cellular assembly and organization
CEA-related cell adhesion molecule 1* 81613 CEACAM1 2.08 Cell death; cell signaling; cellular growth and proliferation; cellular movement;
inflammation
olfactory marker protein* 24612 OMP 2.08 Cell signaling
guanine nucleotide binding protein,
alpha z subunit*
25740 GNAZ 2.05 Cell signaling; cellular development; cellular movement; molecular transport;
biomolecule metabolism
phosphodiesterase 1C* 81742 PDE1C 2.04 Others/unclassified
ribosomal protein S3a* 29288 RPS3A 2.04 Cell death; cellular development; cellular growth and proliferation;
protein synthesis
insulin-like 6* 50546 IL1RAP 1.95 Cell signaling
A kinase (PRKA) anchor protein 14* 60332 AKAP14 1.94 Others/unclassified
CD38 antigen* 25668 CD38 1.94 Cell cycle; cell death; cell signaling; cellular development; cellular growth and
proliferation; cellular movement; biomolecule metabolism; molecular transport;
post–translational modification
p21 (CDKN1A)–activated kinase 1* 29431 PAK1 1.93 Cell death; cell morphology; cell signaling; cellular assembly and organization;
cellular development; cellular movement
regenerating islet–derived 3 alpha* 171162 REG3G 1.93 Others/unclassified
ubiquitin-conjugating enzyme E2I* 25573 UBE2I 1.93 Cell signaling; gene transcription; protein synthesis
ATPase, H+ transporting, V1 subunit F* 116664 ATP6V1F 1.91 Molecular transport
homeo box A1* 25607 HOXA1 1.89 Cell death; cellular development; cellular movement; gene transcription
regenerating islet–derived 3 gamma* 24620 REG3G 1.89 Others/unclassified
Fas apoptotic inhibitory molecule 2* 246274 FAIM2 1.86 Cell death
barrier to autointegration factor 1* 114087 BANF1 1.85 DNA replication, recombination, and repair
thyroid hormone receptor alpha* 81812 THRA 1.85 Biomolecule metabolism; cell death; cell morphology; cellular development; free
radical scavenging; gene transcription; protein synthesis
neuromedin B receptor* 25264 NMBR 1.83 Others/unclassified
ATPase, Na+/K+ transporting, beta 2 polypeptide* 24214 ATP1B2 1.82 Others/unclassified
Chondroitin sulfate proteoglycan 5* 50568 CSPG5 1.81 Cell signaling
MAD homolog 7 (Drosophila)* 81516 SMAD7 1.78 Cell death; cell morphology; cell signaling; cellular development; cellular growth
and proliferation; gene transcription
tachykinin receptor 2* 25007 TACR2 1.78 Others/unclassified
alanyl (membrane) aminopeptidase* 81641 ANPEP 1.76 Cell death; cell morphology; cellular development; cellular movement; protein
synthesis
growth hormone–releasing hormone* 29446 GHRH 1.75 Cell morphology; cell signaling; cellular growth and proliferation; biomolecule
metabolism; molecular transport
protein kinase N1* 29355 PKN1 1.75 Cell signaling; cellular growth and proliferation; cellular movement;
gene transcription
slit homolog 3 (Drosophila)* 83467 SLIT3 1.74 Others/unclassified
dopamine receptor 2* 24318 DRD2 1.72 Cell death; cell signaling; cellular growth and proliferation; cellular
movement; gene transcription; inflammation; biomolecule metabolism
glutathione peroxidase 3* 64317 GPX3 1.72 Cellular growth and Proliferation; Post–translational modification; protein synthesis
vasoactive intestinal peptide receptor 1* 24875 VIPR1 1.71 Cell death; cell signaling; cellular growth and proliferation; cellular
movement; biomolecule metabolism; molecular transport
amphiphysin 1* 60668 AMPH 1.70 Cell signaling; cellular assembly and organization; cellular movement;
gene transcription
G protein beta subunit–like* 64226 GBL 1.70 Others/unclassified
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heat shock 70 kDa protein 5* 25617 HSPA5 1.69 Cell death; cellular growth and proliferation; inflammation
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and
steroid delta-isomerase 1*
29632 HSD3B2 1.68 Others/unclassified
POU domain, class 3, transcription factor 2* 29588 POU3F2 1.68 Cellular development; cellular growth and proliferation; cellular
movement; gene transcription
ribosomal protein S9* 81772 RPS9 1.64 Protein synthesis
glucocorticoid modulatory element binding protein 2* 83635 GMEB2 1.63 Gene transcription
glutamate receptor, ionotropic, NMDA2B* 24410 GRIN2B 1.63 Cell signaling
solute carrier family 8 (sodium/calcium exchanger),
member 3*
140448 SLC8A3 1.63 Cell death; cell signaling
ATPase, Ca2+ transporting, ubiquitous* 25391 ATP2A3 1.62 Others/unclassified
CTD-binding SR-like rA1* 56081 SR-A1 1.60 Others/unclassified
solute carrier family 2 (facilitated glucose transporter),
member 2*
25351 SLC2A2 1.60 Cell death
calcineurin binding protein 1* 94165 CABIN1 1.59 Cell cycle; cell death; cell morphology; cell signaling; cellular development;
cellular growth and proliferation; cellular movement; DNA replication,
recombination, and repair; gene transcription; inflammation; biomolecule
metabolism; molecular transport
heterogeneous nuclear ribonucleoprotein A1* 29578 LOC144983 1.59 Others/unclassified
casein kinase 1, gamma 1* 64086 CSNK1G1 1.57 Others/unclassified
potassium inwardly rectifying channel, subfamily J,
member 10*
29718 KCNJ10 1.56 Cell morphology; cellular development; inflammation; molecular transport
potassium large conductance calcium–activated
channel, subfamily M, beta member 1*
29747 KCNMB1 1.56 Cell signaling; molecular transport
potassium voltage–gated channel, Shaw-related
subfamily, member 3*
117101 KCNC3 1.56 Molecular transport
CCAAT/enhancer binding protein (C/EBP), delta* 25695 CEBPD 1.55 Cell death; cellular development; cellular growth and proliferation; gene
transcription; inflammation
guanine nucleotide binding protein, beta 3* 60449 GNB3 1.55 Cell signaling
ribosomal protein S19* 29287 RPS19 1.54 Cellular development; cellular growth and proliferation; cellular movement;
protein synthesis
aquaporin 5* 25241 AQP5 1.53 Inflammation
chloride channel Kb* 79430 CLCNKB 1.53 Others/unclassified
fatty acid binding protein 3* 79131 FABP3 1.52 Cellular growth and proliferation; biomolecule metabolism;
molecular transport
endothelial differentiation, lysophosphatidic acid
G-protein–coupled receptor, 2*
116744 EDG2 1.51 Cell death; cell morphology; cell signaling; cellular development; cellular growth
and proliferation; cellular movement; gene transcription
killer cell lectin–like receptor subfamily B member 1B* 25192 KLRB1 1.51 Cell death
suppression of tumorigenicity 18* 266680 ST18 1.50 Gene transcription
pregnancy upregulated nonubiquitously expressed
CaM kinase*
29660 PNCK 1.49 Others/unclassified
Arg/Abl–interacting protein ArgBP2* 114901 SORBS2 1.48 Cell death; cell morphology; cell signaling
sodium channel, voltage-gated, type IV,
alpha polypeptide*
25722 SCN4A 1.48 Molecular transport
calcitonin/calcitonin–related polypeptide, alpha * 24241 CALCA 1.47 Cell cycle; cell death; cell morphology; cell signaling; cellular development;
cellular growth and proliferation; cellular movement; DNA replication,
recombination, and repair; gene transcription; inflammation; biomolecule
metabolism; molecular transport
RASD family, member 2* 171099 RASD2 1.47 Others/unclassified
spondin 1* 64456 SPON1 1.46 Others/unclassified
sulfotransferase family, cytosolic, 1C, member 2* 171072 SULT1C2 1.46 Others/unclassified
acyl-CoA synthetase long-chain family member 4* 113976 ACSL4 1.45 Cell death
aldehyde dehydrogenase family 1, subfamily A2* 116676 ALDH1A2 1.45 Cell death; cellular development; cellular growth and proliferation;
biomolecule metabolism
CD3 antigen, zeta polypeptide* 25300 CD247 1.45 Cell death; cell morphology; cell signaling; cellular development; cellular growth
and proliferation; gene transcription; inflammation; post–translational
modification
discs, large homolog 4 (Drosophila)* 29495 DLG4 1.45 Cell signaling; cellular assembly and organization
calmodulin 3 24244 CALM3 1.43 Cell signaling; cellular growth and proliferation
carboxypeptidase E* 25669 CPE 1.43 Biomolecule metabolism; molecular transport
phosphofructokinase, muscle* 65152 PFKM 1.42 Others/unclassified
translocase of outer mitochondrial membrane 20
homology (yeast)*
266601 TOMM20 1.42 Others/unclassified
complement component 1, q subcomponent,
beta polypeptide*
29687 C1QB 1.40 Others/unclassified
regulator of G-protein signaling 19* 59293 RGS19 1.40 Cell signaling; cellular development; biomolecule metabolism;
protein synthesis
Carcinoembryonic antigen gene family (CGM3)* 24256 PSG18 1.39 Others/unclassified
gamma-glutamyl hydrolase* 25455 GGH 1.39 Others/unclassified
N-acetyltransferase 8 (camello like)* 64570 NAT8 1.37 Others/unclassified
pyrimidinergic receptor P2Y, G-protein–coupled, 6* 117264 P2RY6 1.37 Others/unclassified
protein tyrosine phosphatase, receptor type, K,
extracellular region*
360302 PTPRK 1.36 Cellular growth and proliferation
cytochrome P450, 4a12* 266674 CYP4A22 1.35 Others/unclassified
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gamma-aminobutyric acid A receptor, alpha 1* 29705 GABRA1 1.35 Cell morphology; cell signaling
ferritin, heavy polypeptide 1* 25319 FTH1 1.34 Cell death; cell morphology; cellular growth and proliferation; DNA replication,
recombination, and repair; free radical scavenging; cell death; cell morphology;
cellular growth and proliferation; free radical scavenging
guanylate cyclase 1, soluble, beta 2* 25206 GUCY1B2 1.34 Others/unclassified
proteasome (prosome, macropain) 28 subunit, beta* 29614 PSME2 1.31 Cell signaling; cellular growth and proliferation
small inducible cytokine A4* 116637 CCL4 1.31 Cell death; cell morphology; cell signaling; cellular development; cellular growth
and proliferation; cellular movement; inflammation biomolecule metabolism
ADP-ribosylation factor 6 * 79121 ARF6 1.30 Cell death; cell morphology; cell signaling; cellular assembly and organization;
cellular movement; biomolecule metabolism; molecular transport; protein
trafficking
mannan-binding lectin serine protease 2 64459 MASP2 1.30 Others/unclassified
dopamine receptor 4* 25432 DRD4 1.29 Cell signaling; biomolecule metabolism; molecular transport
ATP synthase, H+ transporting, mitochondrial F1
complex, delta subunit*
245965 ATP5D 1.26 Energy production; molecular transport; biomolecule metabolism
calponin 1 65204 CNN1 1.26 Cellular assembly and organization; cellular growth and proliferation; cellular
movement
hydroxyacid oxidase 2 (long chain) 84029 HAO2 1.25 Others/unclassified
cytotoxic T-lymphocyte–associated protein 4 63835 CTLA4 1.23 Cell cycle; cell death; cell signaling; cellular development; cellular growth and
proliferation; cellular movement; inflammation
potassium voltage–gated channel, subfamily H
(eag-related), member 7 *
170739 KCNH7 1.23 Others/unclassified
Ras association (RalGDS/AF-6) domain family 5 54355 RASSF5 1.23 Cell cycle; cell death; cellular growth and proliferation
thymopoietin 25359 TMPO 1.22 Cell cycle; cellular assembly and organization; DNA replication, recombination,
and repair; gene transcription
polypyrimidine tract binding protein 1 29497 PTBP1 1.19 Protein synthesis
protein kinase C and casein kinase substrate in
neurons 2
124461 PACSIN2 1.16 Cell morphology; cell signaling; cellular assembly and organization
leptin receptor overlapping transcript 56766 LEPROT 1.15 Others/unclassified
phospholipase C, delta 1 24655 PLCD1 1.15 Biomolecule metabolism; cellular growth and proliferation
synaptonemal complex protein SC65 59101 SC65 1.15 Others/unclassified
ADP-ribosylation factor 5 79117 ARF5 1.14 Molecular transport; protein trafficking
crystallin, beta B2 25422 CRYBB2 1.11 Others/unclassified
prolactin-like protein L 171556 PRLPL 1.10 Others/unclassified
protein phosphatase 3, catalytic subunit, beta isoform 24675 PPP3CB 1.09 Cell death; cellular development; inflammation
calpain 3 29155 CAPN3 1.07 Protein synthesis
cathepsin D 171293 CTSD 1.07 Cell death; cellular growth and proliferation; free radical scavenging; inflammation;
molecular transport; protein synthesis
eukaryotic translation initiation factor 2B, subunit 2 beta 84005 EIF2B2 1.07 Cellular development; cellular growth and proliferation; protein synthesis
calcitonin/calcitonin–related polypeptide, alpha 24241 CALCA −1.13 Cell cycle; cell death; cell morphology; cell signaling; cellular development; cellular
growth and proliferation; cellular movement; DNA replication, recombination,
and repair; gene transcription; inflammation; biomolecule metabolism;
molecular transport
forkhead box M1 58921 FOXM1 −1.13 Cell cycle; cell death; cell morphology; cellular growth and proliferation; gene
transcription
adrenal secretory serine protease precursor 64565 TMPRSS11D −1.14 Others/unclassified
MAP-kinase activating death domain 94193 MADD −1.19 Cell death; cellular growth and proliferation
calmodulin 3 24244 CALM3 −1.22 Cell signaling; cellular growth and proliferation
neural visinin–like Ca2+–binding protein type 3* 50871 HPCAL1 −1.28 Others/unclassified
fertility protein SP22 117287 PARK7 −1.30 Cell death; cell signaling; cellular growth and proliferation
actin, beta* 81822 ACTB −1.31 Cellular growth and proliferation; cellular movement
G-protein–coupled receptor 37* 117549 GPR37 −1.33 Cell death; cell signaling
glycogen synthase kinase 3 alpha* 50686 GSK3A −1.34 Cellular movement
ribosomal protein L22 81768 RPL22 −1.34 Protein synthesis
actinin alpha 4* 63836 ACTN4 −1.35 Cell death; cellular growth and proliferation; cellular movement
midline 1* 54252 MID1 −1.35 Cellular assembly and organization
dipeptidase 1 (renal)* 94199 DPEP1 −1.36 Others/unclassified
polymeric immunoglobulin receptor* 25046 PIGR −1.36 Cell signaling; cellular growth and proliferation; cellular movement
adducin 2 (beta)* 24171 ADD2 −1.38 Cellular development; cellular growth and proliferation; inflammation;
molecular transport
c-mer protooncogene tyrosine kinase * 65037 MERTK −1.38 Cell death; cell morphology; cell signaling; cellular development; cellular
growth and proliferation
caspase 7* 64026 CASP7 −1.39 Cell death; protein synthesis
ddx5 gene 287765 DDX5 −1.40 Cell death; cellular growth and proliferation; gene transcription
vesicle docking protein* 56042 VDP −1.40 Cellular assembly and organization; molecular transport; protein trafficking
acetylcholinesterase * 83817 ACHE −1.41 Cell death; cell morphology; cell signaling; cellular development; cellular
growth and proliferation; DNA replication, recombination, and repair;
post–translational modification; protein synthesis
phenylalkylamine Ca2+ antagonist (emopamil)
binding protein*
117278 EBP −1.41 Cellular development
phosphodiesterase 4C, cAMP-specific* 290646 PDE4C −1.41 Inflammation
transition protein 2* 24840 TNP2 −1.44 Others/unclassified
casein kinase 1, alpha 1* 113927 CSNK1A1 −1.45 Cell death
nuclear receptor subfamily 4, group A, member 3 58853 NR4A3 −1.46 Cellular development; cellular growth and proliferation; gene transcription
Table 1. (continued )
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phospholipase C, beta 3* 29322 PLCB3 −1.46 Biomolecule metabolism; cellular movement; molecular transport
myelin-associated oligodendrocytic basic protein* 25037 MOBP −1.47 Others/unclassified
retinoic acid receptor, alpha* 24705 RARA −1.47 Cell death; cell signaling; cellular development; cellular growth and proliferation;
cellular movement; biomolecule metabolism; gene transcription; inflammation
putative pheromone receptor Go-VN13C* 286986 EG665255 −1.48 Others/unclassified
prolyl 4-hydroxylase, beta polypeptide* 25506 P4HB −1.49 Cell death
protein kinase, lysine-deficient 1* 116477 WNK1 −1.49 Molecular transport
Pyruvate carboxylase* 25104 PC −1.49 Others/unclassified
ribosomal protein S15* 29285 RPS15 −1.49 Others/unclassified
ATP synthase, H+ transporting, mitochondrial F1
complex, O subunit*
192241 ATP5O −1.50 Others/unclassified
granzyme M (lymphocyte met-ase 1)* 29252 GZMM −1.50 Cell death
metastasis-associated 1* 64520 MTA1 −1.50 Cell morphology; cell signaling; cellular growth and proliferation; cellular
movement; gene transcription
Rous sarcoma oncogene* 83805 SRC −1.50 Cell death; cell morphology; cell signaling; cellular development; cellular growth
and proliferation; cellular movement; gene transcription; biomolecule metabolism;
molecular transport; protein synthesis
neurexophilin 3* 59315 NXPH3 −1.51 Others/unclassified
phosphodiesterase 4A* 25638 PDE4A −1.51 Cell death; cell signaling; cellular development; inflammation; molecular transport;
biomolecule metabolism
calcium channel, voltage-dependent, alpha 1I subunit* 56827 CACNA1I −1.52 Cell signaling
transient receptor potential cation channel, subfamily C,
member 4*
84494 TRPC4 −1.53 Others/unclassified
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide*
29753 YWHAE −1.53 Cell cycle; cell signaling; cellular movement
polymerase (RNA) II (DNA-directed) polypeptide G* 117017 POLR2G −1.54 Gene transcription
F-box only protein 2* 85273 FBXO2 −1.55 Cellular growth and proliferation; protein synthesis
apolipoprotein C-I* 25292 APOC1 −1.56 Biomolecule metabolism; molecular transport
proprotein convertase subtilisin/kexin type 3* 54281 FURIN −1.56 Cell signaling; cellular growth and proliferation; cellular movement; protein synthesis
chemokine orphan receptor 1* 84348 CXCR7 −1.57 Cellular growth and proliferation; cellular movement
heat shock protein, alpha-crystallin–related, B6* 192245 HSPB6 −1.57 Others/unclassified
interleukin 5* 24497 IL5 −1.57 Cell cycle; cell death; cell morphology; cell signaling; cellular development;
cellular growth and proliferation; cellular movement; gene transcription;
molecular transport
interleukin enhancer binding factor 3* 84472 ILF3 −1.57 Cellular growth and proliferation; gene transcription
protein tyrosine phosphatase, receptor type, F* 360406 PTPRF −1.57 Cell cycle; cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular growth and proliferation; cellular movement
par-3 (partitioning defective 3) homolog (C. elegans)* 81918 PARD3 −1.58 Cell morphology; cell signaling; cellular development; gene Transcription
ribosomal protein L27* 64306 RPL27 −1.58 Others/unclassified
linker for activation of T cells* 81511 LAT −1.59 Biomolecule metabolism; cell death; cell morphology; cell signaling; cellular
development; gene transcription; molecular transport
nuclear factor I/C* 29228 NFIC −1.59 Gene transcription
potassium voltage–gated channel, shaker-related
subfamily, beta member 1*
29737 KCNAB1 −1.59 Molecular transport
Bcl2-associated X protein* 24887 BAX −1.60 Cell cycle; cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular development; cellular growth and proliferation; cellular
response to therapeutics; DNA replication, recombination, and repair; free
radical scavenging; inflammation; biomolecule metabolism; molecular transport
carboxylesterase 1* 29225 ES22 −1.60 Others/unclassified
ribosomal protein L10A* 81729 RPL10A −1.60 Others/unclassified
upstream of NRAS* 117180 CSDE1 −1.60 Others/unclassified
nucleoporin 62* 65274 NUP62 −1.61 Cell death; cell signaling; cellular growth and proliferation; gene transcription
eukaryotic translation initiation factor 2B, subunit
4 delta*
117019 EIF2B4 −1.62 Cellular development; protein synthesis
apolipoprotein A–V* 140638 APOA5 −1.63 Biomolecule metabolism; molecular transport
myosin IE* 25484 MYO1E −1.64 Others/unclassified
paired box gene 8* 81819 PAX8 −1.64 Cellular development; gene transcription
prion protein* 24686 PRNP −1.64 Cell death; cellular development; cellular growth and proliferation; cellular movement
amelogenin X chromosome* 29160 AMELX −1.67 Others/unclassified
Unc4.1 homeobox (C. elegans)* 29375 UNCX4.1 −1.67 Cell death
cofilin 1* 29271 CFL1 −1.68 Cell morphology; cell signaling; cellular assembly and organization; cellular
development; cellular growth and proliferation; cellular movement; molecular
transport; protein trafficking
caudal type homeo box 1* 171042 CDX1 −1.69 Others/unclassified
phosphatidylinositol-4-phosphate 5-kinase, type II, alpha* 116723 PIP5K2A −1.70 Biomolecule metabolism; molecular transport
platelet-activating factor acetylhydrolase, isoform 1b,
alpha1 subunit*
114113 PAFAH1B3 −1.70 Cell death; cellular development; biomolecule metabolism
protein tyrosine phosphatase, nonreceptor type substrate 1* 25528 SIRPA −1.70 Cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular development; cellular growth and proliferation;
cellular movement; gene transcription; inflammation
acetylcholinesterase* 83817 ACHE −1.71 Cell death; cell morphology; cell signaling; cellular development; cellular
growth and proliferation; DNA replication, recombination, and repair;
post–translational modification; protein synthesis
ribosomal protein L36* 58927 RPL36 −1.71 Others/unclassified
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G-protein–coupled receptor 24* 83567 MCHR1 −1.72 Cell signaling; molecular transport; biomolecule metabolism
epididymal retinoic acid–binding protein* 29552 LCN5 −1.73 Biomolecule metabolism
gap junction membrane channel protein beta 4* 117055 GJB4 −1.75 Others/unclassified
zinc finger protein 111* 170849 ZNF227 −1.75 Others/unclassified
cleavage and polyadenylation–specific factor 4* 252943 CPSF4 −1.76 Cellular growth and proliferation
ADP-ribosylation factor 1* 64310 ARF1 −1.77 Cellular assembly and organization; cellular growth and proliferation;
biomolecule metabolism; molecular transport; protein trafficking
coagulation factor X* 29243 F10 −1.77 Cell signaling; cellular movement; inflammation; biomolecule metabolism;
molecular transport
ephrin A1* 94268 EFNA1 −1.77 Cell death; cell morphology; cell signaling; cellular assembly and organization;
cellular development; cellular growth and proliferation; cellular movement
rabaptin 5* 54190 RABEP1 −1.78 Others/unclassified
allograft inflammatory factor 1* 29427 AIF1 −1.79 Cell death; cell morphology; cellular development; cellular growth
and proliferation
Cbp/p300–interacting transactivator with Glu/Asp–rich
carboxy-terminal domain 1*
64466 CITED1 −1.79 Cellular development; cellular growth and proliferation; gene transcription
testis enhanced gene transcript* 24822 TEGT −1.79 Cell death
neurogenic differentiation 2* 54276 NEUROD2 −1.80 Cellular development; gene transcription
heat shock 10 kDa protein 1* 25462 HSPE1 −1.83 Cell death
hsp70-interacting protein* 246146 HSPBP1 −1.83 Others/unclassified
calreticulin* 64202 CALR −1.84 Cell death; cellular assembly and organization; cellular development;
cellular growth and proliferation; cellular movement; gene transcription;
molecular transport; protein trafficking
discoidin domain receptor family, member 1* 25678 DDR1 −1.84 Cell death; cellular development; cellular growth and proliferation;
cellular movement
myosin ID* 25485 MYO1D −1.84 Others/unclassified
ribosomal protein L28* 64638 RPL28 −1.84 Others/unclassified
gap junction membrane channel protein alpha 3* 79217 GJA3 −1.85 Cell morphology; cell signaling; cellular development
hairy and enhancer of split 3 (Drosophila)* 64628 HES3 −1.85 Cellular development; gene transcription
ornithine decarboxylase antizyme 1* 25502 OAZ1 −1.87 Cell death; cellular growth and proliferation
a disintegrin and metallopeptidase domain 1a* 56777 ADAM1A −1.89 Cellular movement
mucosal vascular addressin cell adhesion molecule 1* 54266 MADCAM1 −1.89 Cell signaling; cellular development; cellular movement; inflammation
membrane protein, palmitoylated 3 (MAGUK p55
subfamily member 3)*
114202 MPP3 −1.90 Others/unclassified
sulfotransferase family 4A, member 1* 58953 SULT4A1 −1.90 Others/unclassified
CCAAT/enhancer binding protein (C/EBP), alpha* 24252 CEBPA −1.91 Cell cycle; cell death; cellular development; cellular growth and proliferation;
cellular response to therapeutics; gene transcription; biomolecule
metabolism; molecular transport
SNF-related kinase* 170837 SNRK −1.92 Cellular development
ADP-ribosylation factor 3* 140940 ARF3 −1.94 Molecular transport; protein trafficking
aspartyl-tRNA synthetase* 116483 DARS −1.94 Cell cycle; cell signaling; protein synthesis
glycine cleavage system protein H (aminomethyl carrier)* 171133 GCSH −1.94 Biomolecule metabolism; post–translational modification
3-hydroxyisobutyrate dehydrogenase* 63938 HIBADH −1.96 Others/unclassified
preoptic regulatory factor-2* 286903 KIAA1688 −1.96 Others/unclassified
amino-terminal enhancer of split* 29466 AES −1.97 Cell death; gene transcription
ribosomal protein L29* 29283 RPL29 −1.99 Others/unclassified
quinoid dihydropteridine reductase* 64192 QDPR −2.01 Others/unclassified
complexin 2* 116657 CPLX2 −2.02 Cellular assembly and organization; cellular movement
hairy and enhancer of split 2 (Drosophila)* 29567 HES2 −2.02 Gene transcription
transmembrane 4 superfamily member 11* 64364 PLLP −2.02 Molecular transport
ferritin light chain 1* 29292 FTL −2.03 Cellular growth and proliferation
growth hormone–releasing hormone receptor* 25321 GHRHR −2.04 Cell signaling; cellular growth and proliferation; molecular transport;
biomolecule metabolism
membrane protein, palmitoylated 2 (MAGUK p55
subfamily member 2)*
85275 MPP2 −2.04 Cell signaling
ribosomal protein S27* 94266 RPS27 −2.05 Cell signaling; cellular growth and proliferation; protein synthesis
translocase of inner mitochondrial membrane 22
homolog (yeast)*
79463 TIMM22 −2.06 Others/unclassified
sec22 homolog* 117513 SEC22A −2.08 Molecular transport; protein trafficking
transmembrane protein with EGF-like and two
follistatin-like domains 1*
63845 TMEFF1 −2.11 Cellular growth and proliferation
paired-like homeodomain transcription factor 3* 29609 PITX3 −2.12 Cellular development; gene transcription
fibrinogen, gamma polypeptide* 24367 FGG −2.25 Cell signaling
neurogenic differentiation 1* 29458 NEUROD1 −2.26 Cell death; cell morphology; cell signaling; cellular development; cellular
growth and proliferation; cellular movement; gene transcription
steroid-sensitive gene 1* 64387 CCDC80 −2.31 Others/unclassified
ubiquitin A-52 residue ribosomal protein fusion
product 1*
64156 UBA52 −2.33 Gene transcription; protein synthesis
synuclein, gamma* 64347 SNCG −2.42 Cell death; cell morphology; cellular growth and proliferation; cellular movement
*The change in expression was significant compared with untreated control (P < .05). Gene names in italics are common in both panels of T + E2–treated LP and T + DES–treated VP.
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Table 2. T + DES–Induced VP Dysplasia Panel: Genes Whose Expression Selectively Changed following T + DES Treatment in the VPs Harboring Dysplasia, but not in the LPs.
Gene Names Locus ID Symbol Fold Changes Functions
glutathione peroxidase 3* 64317 GPX3 17.188 Cellular development; cellular growth and proliferation;
post–translational modification; protein synthesis
ferritin, heavy polypeptide 1* 25319 FTH1 6.304 Cell death; cell morphology; cellular growth and proliferation; DNA
replication, recombination, and repair; free radical scavenging;
post–translational modification
protein phosphatase 2a, catalytic subunit,
alpha isoform*
24672 PPP2CA 3.388 Biomolecule metabolism; cell death; cellular growth and proliferation;
post–translational modification
monocarboxylate transporter* 80878 SLC16A3 2.263 Others/unclassified
nuclease-sensitive element binding protein 1* 29206 NSEP1 1.898 Cell death; gene transcription
thymopoietin* 25359 TMPO 1.814 Cell cycle; DNA replication, recombination, and repair;
gene transcription
homeo box A1* 25607 HOXA1 1.586 Cell death; cellular development; cellular movement; gene transcription
cystatin C* 25307 CST3 1.585 Cell death; cellular development; cellular growth and proliferation
thyroid hormone receptor alpha * 81812 THRA 1.583 Cell death; cell morphology; cellular development; free radical
scavenging; gene transcription
tubulin, alpha 1* 64158 TUBA1A 1.580 Inflammation
phospholipase C, delta 1* 24655 PLCD1 1.532 Cellular growth and proliferation
glutamate receptor, metabotropic 7* 81672 GRM7 1.481 Cell signaling
potassium voltage–gated channel, subfamily H (eag-related),
member 7 *
170739 KCNH7 1.481 Others/unclassified
plasminogen activator, urokinase* 25619 PLAU 1.461 Cell cycle; cell death; cell morphology; cell signaling; cellular assembly
and organization; cellular development; cellular growth and
proliferation; cellular movement; inflammation
vesicle-associated membrane protein 2 24803 VAMP2 1.452 Cell signaling; cellular assembly and organization; cellular movement;
molecular transport
glyceraldehyde-3-phosphate dehydrogenase* 24383 GAPDH 1.401 Others/unclassified
protein phosphatase 1F (PP2C domain containing)* 287931 PPM1F 1.392 Biomolecule metabolism; cell death; post–translational modification
tumor protein p53* 24842 TP53 1.379 Cell cycle; cell death; cell morphology; cell signaling; cellular assembly
and; organization; cellular development; cellular growth and
proliferation; cellular movement; cellular response to therapeutics;
DNA replication, recombination, and repair; free radical scavenging;
gene transcription; inflammation; post–translational modification;
protein synthesis
opioid receptor, mu 1* 25601 OPRM1 1.375 Cell death; cell signaling; cellular growth and proliferation; cellular
movement; inflammation
calcitonin/calcitonin–related polypeptide, alpha * 24241 CALCA 1.361 Cell cycle; cell death; cell morphology; cell signaling; cellular
development; cellular growth and proliferation; cellular movement;
DNA replication, recombination, and repair; gene transcription;
inflammation
testis-specific protein* 192229 C3ORF34 1.357 Others/unclassified
eukaryotic translation initiation factor 2B, subunit 2 beta * 84005 EIF2B2 1.334 Cellular development; cellular growth and proliferation
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, eta polypeptide*
25576 YWHAH 1.333 Cellular assembly and organization; gene transcription
glucagon-like peptide 1 receptor 25051 GLP1R 1.328 Cell death; gene transcription; inflammation
transient receptor potential cation channel, subfamily C,
member 2*
64573 TRPC2 1.322 Others/unclassified
dopamine receptor 4 * 25432 DRD4 1.311 Cell signaling
early growth response 3* 25148 EGR3 1.289 Cell death; cell signaling; cellular development; cellular growth
and proliferation; gene transcription
glutamate receptor, ionotropic, NMDA2B * 24410 GRIN2B 1.248 Cell morphology; cell signaling
chemokine (C–X–C motif ) ligand 5* 60665 CXCL6 1.236 Cell signaling; cellular movement
myosin IC 65261 MYO1C 1.190 Cell morphology
breast cancer anti–estrogen resistance 1 25414 BCAR1 1.190 Cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular development; cellular growth and proliferation;
cellular movement
aryl hydrocarbon receptor nuclear translocator 2 25243 ARNT2 1.172 Gene transcription
CCAAT/enhancer binding protein (C/EBP), delta 25695 CEBPD 1.151 Cell cycle; cell death; cellular development; cellular growth and
proliferation; gene transcription; inflammation; biomolecule
metabolism; molecular transport
CTD-binding SR-like rA1 56081 SR-A1 1.148 Others/unclassified
ADP-ribosylation factor 6 79121 ARF6 1.142 Cell death; cell morphology; cellular assembly and organization;
cellular movement
calmodulin 3 24244 CALM3 1.138 Cell death; cellular growth and proliferation; post–translational
modification
synaptotagmin 3 25731 SYT3 1.115 Cell signaling; cellular assembly and organization; cellular movement;
molecular transport
dynein, cytoplasmic, light chain 1 58945 DYNLL1 1.090 Cell death; cell morphology; cellular assembly and organization
MAD homolog 7 (Drosophila) 81516 SMAD7 1.062 Cell cycle; cell death; cell morphology; cellular development; cellular
growth and proliferation; cellular movement; gene transcription
v-maf musculoaponeurotic fibrosarcom oncogene
family, protein B (avian)
54264 MAFB 1.062 Cell death; cellular development; cellular movement;
gene transcription
calmodulin 3 24244 CALM3 1.060 Cellular growth and proliferation; post–translational modification
thymosin, beta 10 50665 TMSB10 1.059 Cell death; cellular assembly and organization; cellular
growth and proliferation
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aldehyde dehydrogenase family 1, subfamily A2 116676 ALDH1A2 1.035 Cell death; cellular development; cellular growth and proliferation
syntaxin 1B2 24923 STX1B2 1.032 Others/unclassified
aldolase A 24189 ALDOA −1.013 Others/unclassified
prosaposin 25524 PSAP −1.031 Cell cycle; cell death; cellular growth and proliferation; biomolecule
metabolism; molecular transport; post–translational modification
vesicle-associated membrane protein 2 24803 VAMP2 −1.031 Cell death; cell signaling; cellular assembly and organization; cellular
movement; molecular transport
Rous sarcoma oncogene 83805 SRC −1.070 Biomolecule metabolism; cell cycle; cell death; cell morphology; cell
signaling; cellular assembly and organization; cellular development;
cellular growth and proliferation; cellular movement; DNA
replication, recombination, and repair; gene transcription; molecular
transport; post–translational modification
acetylcholinesterase 83817 ACHE −1.072 Cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular development; cellular growth and proliferation;
DNA replication, recombination, and repair; post–translational
modification; protein synthesis
Max interacting protein 1 25701 MXI1 −1.120 Cell morphology; cellular growth and proliferation; gene transcription
betacellulin 64022 BTC −1.137 Cell cycle; cell death; cell signaling; cellular development; cellular
growth and proliferation; cellular movement; DNA replication,
recombination, and repair
argininosuccinate synthetase 25698 ASS1 −1.165 Others/unclassified
nuclear receptor subfamily 1, group D, member 2 259241 NR1D2 −1.170 Gene transcription
stannin 29140 SNN −1.242 Cell death
phosphatase and tensin homolog* 50557 PTEN −1.272 Cell cycle; cell death; cell morphology; cell signaling; cellular assembly
and organization; cellular development; cellular growth and
proliferation; cellular movement; gene transcription inflammation;
biomolecule metabolism; molecular transport; post–translational
modification
solute carrier family 17 (sodium-dependent inorganic
phosphate cotransporter), member 7*
116638 SLC17A7 −1.287 Cell signaling
carnitine palmitoyltransferase 1, liver* 25757 CPT1A −1.291 Biomolecule metabolism
isopentenyl-diphosphate delta isomerase* 89784 IDI1 −1.294 Others/unclassified
LIM homeobox protein 5 124451 LHX5 −1.317 Others/unclassified
calpain, small subunit 1* 29156 CAPNS1 −1.318 Cell death; cellular assembly and organization; cellular growth and
proliferation; cellular movement
filaggrin 24641 FLG −1.325 Cellular assembly and organization
microsomal glutathione S-transferase 1 171341 MGST1 −1.329 Biomolecule metabolism
protein tyrosine phosphatase, nonreceptor type substrate 1* 25528 SIRPA −1.330 Cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular development; cellular growth and proliferation;
cellular movement; gene transcription; inflammation
neurofibromatosis 2 25744 NF2 −1.333 Cell death; cellular growth and proliferation; cellular movement
Notch gene homolog 3 (Drosophila)* 56761 NOTCH3 −1.335 Cellular development; gene transcription
killer cell lectin–like receptor subfamily B member 1B* 25192 KLRB1 −1.338 Cell death
basic transcription element binding protein 1* 117560 KLF9 −1.339 Gene transcription
regulating synaptic membrane exocytosis 1* 84556 RIMS1 −1.353 Cell morphology; cell signaling; cellular assembly and organization;
cellular movement; molecular transport
transglutaminase 1* 60335 TGM1 −1.376 Biomolecule metabolism; cell death; cellular development;
post–translational modification
translocase of inner mitochondrial membrane 23
homolog (yeast)*
54312 TIMM23 −1.393 Others/unclassified
lysozyme 25211 LYZ −1.399 Others/unclassified
solute carrier family 25 (mitochondrial carrier;
oxoglutarate carrier), member 11*
64201 SLC25A11 −1.407 Others/unclassified
hydroxysteroid 11-beta dehydrogenase 1* 25116 HSD11B1 −1.407 Cellular development; cellular growth and proliferation
potassium intermediate/small conductance
calcium–activated channel, subfamily N, member 3*
54263 KCNN3 −1.412 Cell signaling
B-cell leukemia/lymphoma 2* 24224 BCL2 −1.413 Cell cycle; cell death; cell morphology; cell signaling; cellular assembly
and organization; cellular development; cellular growth and
proliferation; cellular movement; cellular response to therapeutics;
DNA replication, recombination, and repair; biomolecule
metabolism; gene transcription; inflammation; molecular transport;
post–translational modification
hyperpolarization-activated, cyclic nucleotide–gated
K+ 4*
59266 HCN4 −1.415 Cell signaling
perforin 1 (pore-forming protein)* 50669 PRF1 −1.417 Cell death; cell morphology; cell signaling; DNA replication,
recombination, and repair; inflammation
calcitonin/calcitonin–related polypeptide, alpha* 24241 CALCA −1.433 Cell morphology; cell signaling; cellular development;
cellular growth and proliferation; cellular movement;
DNA replication, recombination, and repair; gene
transcription; inflammation
nuclear RNA export factor 1* 59087 NXF1 −1.436 Protein synthesis
fibroblast growth factor 14* 63851 FGF14 −1.439 Others/unclassified
solute carrier family 7 (cationic amino acid transporter,
y+ system), member 3*
29485 SLC7A3 −1.455 Others/unclassified
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ATP synthase, H+ transporting, mitochondrial F0
complex, subunit b, isoform 1*
171375 ATP5F1 −1.456 Cellular growth and proliferation
septin 3* 56003 SEPT3 −1.468 Others/unclassified
cholinergic receptor, nicotinic, beta polypeptide 2
(neuronal)*
54239 CHRNB2 −1.469 Cell signaling
wild-type p53–induced gene 1* 64394 ZMAT3 −1.480 Cell death; cellular growth and proliferation; DNA
replication, recombination, and repair
glutamate receptor, ionotropic, kainate 4* 24406 GRIK4 −1.482 Cell signaling
Kruppel-like factor 15* 85497 KLF15 −1.488 Gene transcription
aquaporin 6* 29170 AQP6 −1.496 Others/unclassified
unc-5 homolog A (C. elegans)* 60629 UNC5A −1.498 Cell death
integrin beta 4* 25724 ITGB4 −1.502 Cell death; cell morphology; cellular assembly and organization; cellular
development; cellular growth and proliferation; cellular movement;
gene transcription
peptidylprolyl isomerase A* 25518 PPIA −1.526 Cell death; cellular development; cellular growth and proliferation;
cellular movement; DNA replication, recombination, and repair;
inflammation; post–translational modification
FXYD domain–containing ion transport regulator 6* 63847 FXYD6 −1.562 Others/unclassified
ribosomal protein L37* 81770 RPL37 −1.579 Others/unclassified
RT1 class II, locus Da* 294269 HLA-DRA −1.580 Cell signaling; inflammation
FK506 binding protein 12-rapamycin–associated
protein 1*
56718 FRAP1 −1.596 Biomolecule metabolism; cell cycle; cell death; cell morphology; cell
signaling; cellular development; cellular growth and proliferation;
cellular movement; gene transcription; inflammation; post–translational
modification; protein synthesis
eukaryotic translation elongation factor 1 alpha 1* 171361 EEF1A1 −1.618 Cell death; protein synthesis
glutathione S-transferase theta 1* 25260 GSTT1 −1.622 Biomolecule metabolism
solute carrier family 4, member 1* 24779 SLC4A1 −1.630 Cell death; cellular growth and proliferation
fibroblast growth factor 17* 29368 FGF17 −1.642 Cellular growth and proliferation
forkhead box M1* 58921 FOXM1 −1.646 Cell cycle; cell death; cell morphology; cellular growth and proliferation;
gene transcription
ATPase, class II, type 9A* 84011 ATP9A −1.649 Others/unclassified
phosphorylase kinase, gamma 2 (testis)* 140671 PHKG2 −1.679 Biomolecule metabolism; post–translational modification
arrestin, beta 1* 25387 ARRB1 −1.683 Cellular movement
rhoB gene* 64373 RHOB −1.684 Cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular development; cellular growth and proliferation;
cellular movement; gene transcription
par-3 (partitioning defective 3) homolog (C. elegans) * 81918 PARD3 −1.686 Cell morphology; cell signaling; cellular assembly and organization;
cellular development; gene transcription
ribosomal protein L21* 79449 RPL21 −1.687 Others/unclassified
RAS protein–specific guanine nucleotide–releasing
factor 1*
192213 RASGRF1 −1.715 Cell morphology; cell signaling; cellular growth and proliferation;
gene transcription
acetylcholinesterase * 83817 ACHE −1.741 Cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular development; cellular growth and proliferation;
DNA replication, recombination, and repair; post–translational
modification; protein synthesis
ribosomal protein L18 * 81766 RPL18 −1.741 Others/unclassified
granzyme M (lymphocyte met-ase 1)* 29252 GZMM −1.745 Cell death
Bcl2-associated X protein* 24887 BAX −1.746 Cell cycle; cell death; cell morphology; cellular assembly and
organization; cellular development; cellular growth and proliferation;
cellular response to therapeutics; DNA replication, recombination, and
repair; free radical scavenging; inflammation; biomolecule metabolism;
molecular transport; protein synthesis
legumain* 63865 LGMN −1.749 Cellular movement
RAB6A, member RAS oncogene family * 84379 RAB6A −1.752 Cellular assembly and organization
matrix metalloproteinase 16* 65205 MMP16 −1.763 Cellular movement; inflammation
olfactory receptor 226* 65140 OR6A2 −1.770 Others/unclassified
mitogen-activated protein kinase 14* 81649 MAPK14 −1.775 Biomolecule metabolism; cell cycle; cell death; cell morphology; cellular
development; cellular growth and proliferation; cellular movement;
gene transcription; inflammation; post–translational modification
c-mer protooncogene tyrosine kinase * 65037 MERTK −1.780 Biomolecule metabolism; cell death; cell morphology; cell signaling;
cellular development; cellular growth and proliferation;
post–translational modification
clathrin, heavy polypeptide (Hc)* 54241 CLTC −1.786 Cell morphology; cellular growth and proliferation
transient receptor potential cation channel, subfamily C,
member 4 *
84494 TRPC4 −1.793 Others/unclassified
carnitine palmitoyltransferase 1b* 25756 CPT1B −1.795 Biomolecule metabolism
PDZ and LIM domain 1 (elfin)* 54133 PDLIM1 −1.796 Gene transcription
fatty acid amide hydrolase* 29347 FAAH −1.798 Cell death; inflammation
fatty acid binding protein 4, adipocyte* 79451 FABP4 −1.820 Gene transcription
protein tyrosine phosphatase, nonreceptor type 12* 117255 PTPN12 −1.826 Biomolecule metabolism; cell morphology; cell signaling; cellular
assembly and organization; cellular development; cellular movement;
post–translational modification
potassium voltage–gated channel, Shab-related subfamily,
member 2*
117105 KCNB2 −1.834 Others/unclassified
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glutathione S-transferase, pi 2* 29438 GSTP1 −1.856 Cell death; cellular growth and proliferation; biomolecule metabolism;
gene transcription
Fc receptor, IgG, alpha chain transporter* 29558 FCGRT −1.870 Cell signaling; molecular transport
voltage-gated channel like 1* 266760 VGCNL1 −1.871 Others/unclassified
prostaglandin D2 synthase* 25526 PTGDS −1.888 Cell death; cell morphology
MAP-kinase activating death domain* 94193 MADD −1.934 Cell death; cellular growth and proliferation
neogenin* 81735 NEO1 −1.935 Cellular growth and proliferation; cellular movement; gene transcription
calbindin 1* 83839 CALB1 −1.950 Cell death; cell morphology; cell signaling
guanylate cyclase 2e* 79222 GUCY2D −1.957 Others/unclassified
adrenal secretory serine protease precursor * 64565 TMPRSS11D −1.971 Others/unclassified
ubc2e ubiquitin–conjugating enzyme* 641452 Ube2d2 −1.986 Others/unclassified
neuroblastoma, suppression of tumorigenicity 1* 50594 NBL1 −2.003 Cellular movement
collagen, type 1, alpha 1* 29393 COL1A1 −2.023 Cell morphology; cellular growth and proliferation; cellular movement
homeodomain interacting protein kinase 3* 83617 HIPK3 −2.034 Biomolecule metabolism; cell signaling; post–translational modification
intercellular adhesion molecule 1* 25464 ICAM1 −2.052 Cell death; cell morphology; cell signaling; cellular development;
cellular growth and proliferation; cellular movement; inflammation
cyclin-dependent kinase 5* 140908 CDK5 −2.134 Biomolecule metabolism; cell death; cell morphology; cell signaling;
cellular assembly and organization; cellular development; cellular
growth and proliferation; cellular movement; molecular transport;
post–translational modification
ATPase, Cu2+ transporting, beta polypeptide* 24218 ATP7B −2.137 Cell death
Jun D protooncogene* 24518 JUND −2.159 Cell death; cell morphology; cellular growth and proliferation;
gene transcription
neurexophilin 3* 59315 NXPH3 −2.168 Others/unclassified
heterogeneous nuclear ribonucleoprotein
methyltransferase–like 3 (S. cerevisiae)*
89820 PRMT3 −2.171 Biomolecule metabolism; post–translational modification
midline 1* 54252 MID1 −2.180 Cellular assembly and; organization
ATP-binding cassette, subfamily C (CFTR/MRP),
member 1*
24565 ABCC1 −2.191 Cell death; cellular movement; inflammation; biomolecule
metabolism; molecular transport
prothymosin alpha* 29222 PTMA −2.313 Cell cycle; cell death; cellular development; cellular growth and
proliferation; gene transcription
ubiquilin 1* 114590 UBQLN1 −2.322 Others/unclassified
similar to Leydig cell tumor 10 kDa protein* 288913 C19ORF53 −2.346 Others/unclassified
Inhibitor of DNA binding 2, dominant negative
helix–loop–helix protein*
25587 ID2 −2.357 Cell cycle; cell death; cell morphology; cellular development; cellular
growth and proliferation; cellular movement; gene transcription
lectin, galactose binding, soluble 1* 56646 LGALS1 −2.385 Cell cycle; cell death; cell morphology; cellular development; cellular
growth and proliferation; cellular movement gene transcription;
inflammation; post–translational modification
calreticulin* 64202 CALR −2.401 Cell cycle; cell death; cellular assembly and organization; cellular
development; cellular growth and proliferation; cellular movement;
gene transcription; post–translational modification
carbonic anhydrase 5* 54233 CA5A −2.427 Inflammation
mitogen-activated protein kinase 13* 29513 MAPK13 −2.438 Cell death; cell morphology; gene transcription; inflammation
cytochrome P450, family 19, subfamily a,
polypeptide 1*
25147 CYP19A1 −2.440 Cell death; cell morphology; cellular development; cellular growth and
proliferation; cellular movement; gene transcription; biomolecule
metabolism
nucleobindin 1* 84595 NUCB1 −2.513 Others/unclassified
tropomodulin 2* 58814 TMOD2 −2.563 Cell signaling; cellular assembly and organization
apolipoprotein B editing complex 1* 25383 APOBEC1 −2.655 Others/unclassified
solute carrier family 7 (cationic amino acid transporter,
y+ system), member 7*
83509 SLC7A7 −2.720 Cell signaling; cellular growth and proliferation
hsp70-interacting protein* 246146 HSPBP1 −2.772 Post–translational modification
Rsec5 protein* 171455 EXOC2 −2.779 Cell signaling; molecular transport
MAD homolog 9 (Drosophila)* 85435 SMAD9 −2.815 Others/unclassified
ERM-binding phosphoprotein* 59114 SLC9A3R1 −2.851 Cell signaling; cellular growth and proliferation
low-density lipoprotein receptor–related protein 3* 89787 LRP3 −2.869 Others/unclassified
Rab geranylgeranyl transferase, a subunit* 58983 RABGGTA −2.890 Biomolecule metabolism; post–translational modification
cadherin EGF LAG seven-pass G-type receptor 2* 83465 CELSR2 −2.923 Others/unclassified
tropomyosin 4* 24852 TPM4 −3.019 Cellular movement
cytochrome P450, family 2, subfamily e, polypeptide 1* 25086 CYP2E1 −3.161 Cell death; biomolecule metabolism
CEA-related cell adhesion molecule 9* 116711 CEACAM9 −3.207 Others/unclassified
discoidin domain receptor family, member 2* 83573 DDR2 −3.253 Others/unclassified
phosphoglucomutase 1* 24645 PGM1 −3.308 Others/unclassified
gamma-glutamyl carboxylase* 81716 GGCX −3.455 Post–translational modification
Cplx1 complexin 1* 64832 CPLX1 −3.464 Cell signaling; cellular assembly; and organization; cellular movement;
molecular transport
septin 9* 83788 SEPT9 −3.781 Cell cycle; protein synthesis
matrix metallopeptidase 8* 63849 MMP8 −3.785 Cell death, cellular movement
thyroid hormone receptor interactor 10* 116717 TRIP10 −4.232 Cell death
carboxylesterase 3* 113902 CES1 −4.325 Others/unclassified
cyclin-dependent kinase 2* 362817 CDK2 −4.458 Biomolecule metabolism; cell cycle; cell death; cell morphology;
cellular development; cellular growth and proliferation; DNA
replication, recombination, and repair; gene transcription;
post–translational modification
Table 2. (continued )
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Reverse Transcription and Real-Time Quantitative Polymerase
Chain Reaction
The total RNA from each sample of prostate tissue was reverse-
transcribed into cDNA using Superscript III (Invitrogen, Carlsbad,
CA). Specific primers were designed using either Primer Express 3 (Ap-
plied Biosystems, Foster City, CA) or Primer3 software [28]; the se-
quence of the primer is listed in Table W1. Real-time quantitative
polymerase chain reaction (q-PCR) was performed on the 7900HT
Fast Real-Time PCR System (ABI Biosystems) using the Power SYBR
Green PCR master mix (Applied Biosystems). Polymerase chain reac-
tion was performed in a total volume of 10 μl containing 50 ng of total
cDNA, 1× Power SYBR Green PCR master mix, and a final primer
concentration of 800 nM. The relative expression level was analyzed
by the ΔΔCt method [29] and one-way ANOVA followed by Tukey
post hoc analysis, where P < .05 was considered statistically significant.
Results
T + E2 and T + DES Treatments Differentially Induced
Dysplasia in LP and VP, Respectively
The expected physiological and histologic changes resulting from
T + E2 and T + DES treatment were observed as reported previously
[15,18–20]. Dysplasia was observed in the T + E2–treated LPs
(100% incidence) and T + DES–treated VPs (100% incidence),
whereas no preneoplastic lesions were observed in T + E2–treated
VPs and T + DES LPs. In T + E2–treated LPs, the dysplastic lesions
were often accompanied by inflammatory infiltrates [17].
Hierarchical Clustering Identified Differential Action of E2
and DES in the Two Prostate Lobes
Unsupervised hierarchical clustering was performed for each hor-
mone treatment group (T + E2 or T + DES) to determine the relat-
edness of replicate LP and VP samples (n = 5 per group) according to
similarity in gene expression patterns among the 1063 genes with a
significant difference in expression across samples, without prior
knowledge of gene and sample identity.
Hierarchical clustering of samples showed that all LPs treated with
T + E2 formed one cluster distinct from the cluster containing all
untreated LPs. The hormone treatment, however, did not partition
the hormone-treated and -untreated VPs, which formed a single large
cluster (Figure 1A). These results indicate that the T + E2 treatment
induced changes in gene expression mainly in the LP and had little, if
any, effect on the gene expression pattern in the VP.
In a similar manner, T + DES treatment segregated only the VPs
into two distinct clusters (treated and untreated) and did not par-
tition the LPs into distinctive groups (Figure 1B). These findings
indicate that the hormone treatment altered primarily the gene
expression pattern in the VP and had little effect on LP gene ex-
pression. It is interesting that the gene expression pattern in the
VP after T + DES treatment appeared to more closely resemble that
observed in the LPs, as the T + DES–treated VPs formed a cluster
more closely linked to the LP cluster than the one comprising un-
treated VPs.
Identification of Estrogen-Induced Differentially Expressed
Genes Related to Dysplasia in Rat LP or VP
We used the following criteria to identify two panels of dysplasia-
related genes: 1) the T + E2–induced LP dysplasia panel contains
genes whose expression changed following T + E2 treatment in
the LPs harboring dysplasia but excludes those whose expression
also changed in the VPs with no dysplastic changes (253 genes; Fig-
ure 1C, left; Table 1), and 2) the T + DES–induced VP dysplasia panel
includes genes whose expression changed after T + DES treatment
in the VPs harboring dysplasia but excludes those whose expression
Gene Names Locus ID Symbol Fold Changes Functions
monoamine oxidase B* 25750 MAOB −4.873 Cell death
solute carrier family 6 (neurotransmitter transporter,
betaine/GABA), member 12*
50676 SLC6A12 −5.287 Others/unclassified
peroxiredoxin 1* 117254 PRDX1 −5.360 Cell death; cell morphology; cellular growth and proliferation; gene
transcription; post–translational modification
ADP-ribosylation factor 4* 79120 ARF4 −5.374 Others/unclassified
glypican 3* 25236 GPC3 −5.638 Cell death; cellular growth and proliferation
protein kinase C, delta binding protein* 85332 PRKCDBP −6.059 Others/unclassified
cd86 antigen* 56822 CD86 −6.118 Cell signaling; cellular development; cellular growth and proliferation;
cellular movement; gene transcription; inflammation
Sjogren syndrome antigen B* 81783 SSB −6.131 Gene transcription; protein synthesis
secretoglobin, family 2A, member 1* 25010 PSBP1 −6.227 Others/unclassified
procollagen, type I, alpha 2* 84352 COL1A2 −7.076 Cell morphology
A kinase (PRKA) anchor protein 1* 114124 AKAP1 −8.502 Cell death
methionine adenosyltransferase II, alpha* 171347 MAT2A −9.474 Others/unclassified
FXYD domain–containing ion transport regulator 1* 58971 FXYD1 −9.644 Cellular growth and proliferation; gene transcription
CD24 antigen* 25145 CD24 −11.299 Cell death; cell morphology; cell signaling; cellular assembly and
organization; cellular development; cellular growth and proliferation;
cellular movement
nuclear receptor subfamily 1, group I, member 2* 84385 NR1I2 −11.958 Biomolecule metabolism; gene transcription; inflammation;
molecular transport; post–translational modification
glial cell line derived neurotrophic factor family
receptor alpha 1*
25454 GFRA1 −17.708 Cell death; cell morphology; cellular development; cellular; growth
and proliferation; cellular movement
cell division cycle 25 homolog A (S. cerevisiae)* 171102 CDC25A −19.859 Cell cycle; cell death; cell morphology; cellular growth and
proliferation; dna replication, recombination, and repair
5-hydroxytryptamine (serotonin) receptor 5B* 79247 HTR5B −22.285 Others/unclassified
NSFL1 (p97) cofactor (p47)* 83809 NSFL1C −22.400 Others/unclassified
membrane and microfilament–associated protein p58* 207121 RGD: 727794 −49.533 Cellular assembly and organization
*The change in expression was significant compared with untreated control (P < .05). Gene names in italics are common in both panels of T + E2–treated LP and T + DES–treated VP.
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also changed in the LPs without dysplasia (198 genes; Figure 1C, right;
Table 2).
Image plots (Figure 2, A, and B1 and B2) showed the up- and
downregulated genes in the T + E2–induced LP dysplasia panel
(253 genes), respectively. Although genes in this panel were distrib-
uted among 27 IPA networks, two major networks with the highest
relevancy scores were identified: one related to cell morphology, cel-
lular growth, proliferation, and movement (Figure 2C ), and the other
related to apoptosis and cell signaling (Figure 2D). From these two
networks, six genes were selected for post hoc confirmation by real-
time q-PCR (Figure 3). All six genes showed the predicted expression
patterns. Significant differences (P < .01/.05) were observed between
the transcript levels in the T + E2–treated and –untreated LPs,
whereas no significant differences (P > .05) in the transcript levels
Figure 2. Heat maps and gene interaction networks of differentially expressed genes found exclusively in the LP dysplasia following T +
E2 treatment. Red and green denote upregulated and downregulated expression, respectively, as compared with the overall gene’s
mean value normalized to the universal rat reference RNA. Columns represent data from a single prostate sample, and rows correspond
to a single gene probe. (A) A single cluster of upregulated genes identified in the T + E2 LP dysplasia, marked with pink (left panel); a
selected region (blue box) of this cluster is enlarged (right panel). (B1 and B2) Two separate downregulated gene clusters observed only
in T + E2 LP dysplasia, marked with pink (left panels); selected clusters are magnified (right panels). (C and D) Two representative gene
interaction networks (with the highest relevancy scores) generated by IPA analysis from the differentially expressed genes in the T + E2
LP dysplasia panel. Green indicates downregulated; red, upregulated. Genes bordered in red were validated by real-time q-PCR. See
Figure 1 for key to IPA network.
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were observed between the treated and untreated VP groups. These
genes are the CCAAT/enhancer binding protein-delta (Cebpd ), the
tumor protein Tp53, MAD homolog 7 (Smad7 ), homeobox A1
(Hoxa1), killer cell lectin–like receptor subfamily B member 1
(Klrb1), and neurexophilin 3 (Nxph3). Notably, the q-PCR data
correlated well with those obtained by microarray analyses (Fig-
ure W1A). T + E2–response genes found in VP, in contrast to those
found in the LP, were not mapped to any particular IPA networks
(data not shown).
Image plots illustrated distinctive upregulated (Figure 4A) and
downregulated (Figure 4, B1 and B2) genes in the T + DES–induced
VP dysplasia panel. In addition, a unique set of genes was exclusively
repressed by T + DES in the VP harboring dysplasia (Figure 4B2).
These genes were also underexpressed in LPs compared with the
untreated VPs. Genes in the T + DES–treated VP panel (198 genes)
mapped primarily to two major networks related to 1) apoptosis,
cellular development, growth, and proliferation and 2) estrogen signal-
ing, as they exhibited the highest relevancy scores (Figure 4, C and D,
respectively). From the two networks, nine genes were selected for post
hoc confirmation by q-PCR analyses that correlated well with those
obtained by microarrays (Figure W1B). All nine genes showed signif-
icant increases in transcript levels (P < .01/.05) in the VP with T +
DES treatment and exhibited little or no change in expression (P >
.05) in the LPs of the treated group compared with untreated controls
Figure 3. Post hoc real-time q-PCR analyses of selected genes in the T + E2 LP dysplasia panel. Data were normalized to the levels of
Rpl19. Bars indicate standard deviations (SD) of three to five animals in each treatment group. *P < .05, **P < .01 by one-way ANOVA
with Tukey post hoc analysis.
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(Figure 5). They include Cebpd, Tp53, v-maf musculoaponeurotic fi-
brosarcoma oncogene homolog B (Mafb), Hoxa1, breast cancer anti–
estrogen resistance 1 (Bcar1), plasminogen activator urokinase (Plau),
thyroid hormone receptor alpha (Thra), glutathione peroxidase 3
(Gpx3), and v-src sarcoma viral oncogene homolog (Src).
Only 32 genes were found to be common in both dysplasia-related
panels (Figure 1C ), and 23 (of 32) genes formed a unique gene
network when mapped by IPA (Figure 1D). We postulate that this
gene network is central to E2- or DES-induced dysplasia in the LP
or VP.
Figure 4. Heat maps and gene interaction networks of differentially expressed genes found uniquely in the VP dysplasia following T +
DES treatment. (A) A single cluster of upregulated genes identified only in the T + DES VP dysplasia, marked with pink (left panel), and
the selected cluster enlarged (right panel). (B1 and B2) Clusters of downregulated genes in the VP but not in the LP following T + DES
exposure. Interestingly, a single cluster (B2, left panel) corresponds to the downregulated genes in the T + DES–treated VP and is also
underexpressed in both untreated and treated LPs. A selected region (blue box) of this cluster is enlarged (right panel). (C and D) Two
representative gene interaction networks (with the highest relevancy scores) generated by IPA analysis from the differentially expressed
genes in the T + DES VP dysplasia panel. Green indicates downregulated; red, upregulated. Genes bordered with red were validated by
real-time q-PCR. See Figure 1 for key to IPA network.
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Identification of Estrogen-induced Differentially Expressed
Genes That Are Not Related to Dysplasia in Rat LP or VP
We also identified two sets of hormone-induced genes that are not
related to dysplasia. These genes exhibited differential expression in
the VP following T + E2 treatment (14 genes; Figure 1C, left bottom)
and in the LP following T + DES treatment (190 genes; Figure 1C,
right bottom). They are published in Tables W2 and W3.
Genes Insensitive to the T + E2 and T + DES Treatments
Two sets of 156 and 80 genes were identified as insensitive in the
LP and/or VP to T + E2 or T + DES treatment, respectively (Figure 6,
A–C; Tables W4 and W5). Forty-one genes were found in both
hormone-insensitive panels and mapped to an IPA network (Fig-
ure 6D) that includes the androgen receptor (Ar), a key regulator of
prostate function.
Discussion
Exposure of the human prostate to estrogen may increase as men
age [2–4] or with increased exposure to dietary estrogens such as
DES or zeranol residues in meat, bisphenol A from food containers,
or phytoestrogens [9]. The NBL rat provides a relevant model for
elucidating mechanisms underlying carcinogenesis caused by such ex-
posures, such as dysplasia and PCa, that consistently developed in the
LP or the VP following chronic T–supported treatment with E2 or
DES, respectively [15,18–20]. In the present study, we assessed tran-
scriptional profiles elicited by the xenoestrogen DES in comparison
with those of the endogenous hormone E2 and observed prostatic
lobe–specific differential responses to the two estrogens in NBL rats.
Hierarchical clustering revealed that the T + E2 treatment principally
affects the LP gene expression profile whereas the T + DES targets
that of the VP. Two distinct panels of dysplasia-related genes were
identified: the T + E2 LP panel (253 genes) and the T + DES VP
Figure 5. Post hoc validation of selected genes in the T + DES VP dysplasia panel by real-time q-PCR. The data were normalized to the
levels of Rpl19. Bars indicated standard deviations (SD) of three to five animals in each treatment group. *P < .05, **P < .01 by one-way
ANOVA with Tukey post hoc analysis.
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panel (198 genes), with only 32 overlapping genes. These findings
indicate that the two estrogens alter gene expression profiles only
in the prostatic lobe that develops dysplasia following each of the
hormonal treatments. These findings imply a functional divergence
of the two estrogens with respect to their oncogenic actions in the rat
prostate. Thus, endocrine disruption of gene expression and dysplasia
induction of the two estrogens are categorically different [9], al-
though they may share some biologic convergence [30].
The IPA analysis identified distinct gene interaction networks
based on differential expression profiles. It classified genes into func-
tional categories and suggested a possible mechanistic linkage among
the differentially expressed genes. We also used this tool to help pri-
oritize genes for confirmation. The T + E2 treatment altered the ex-
pression of LP genes primarily in two major networks: one related to
cell morphology, cellular growth, proliferation, and movement, and
the other related to apoptosis and cell signaling. Exposure to T +
DES also affected expression of genes in a similar network associated
with apoptosis, cellular development, growth, and proliferation. In-
triguingly, it also altered the expression of a set of genes linked to E2,
a finding that may explain why, after T + DES treatment, gene ex-
pression profiles in the VP shifted closer to those in the treated and
untreated LPs, which are under the influence of natural estrogen. By
Figure 6. Heat maps of genes insensitive to (A) T + E2 or (B) T + DES. (C) Venn diagram showing the number of genes insensitive to T +
E2 and/or T + DES treatment. Note that 41 genes are found in common in both hormone-insensitive panels and mapped to an IPA
network (D) that includes the Ar, a key regulator of prostate function. Gray indicates no change in gene expression levels compared
with those in untreated counterparts. See Figure 1 for key to IPA network.
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first mapping genes to the IPA network before selecting genes for
confirmation, we were able to validate most of the expression changes
in the microarrays with real-time q-PCR. In this regard, we con-
firmed three genes (Cebpd, Hoxa1, and Tp53) common in the two
dysplasia panels. Importantly, these three genes were upregulated
only in the prostatic lobes that developed dysplasia, i.e., the T +
E2–treated LP and the T + DES–treated VP. Other lobe-specific
genes that were confirmed were Smad7, Klb1, and Nxph3 in the
T + E2–treated LP and Mafb, Src, Bcar1, Gpx3, Plau, and Thra in
T + DES–treated VP. Our findings suggest that these gene expression
changes induced by T + E2/DES treatment could be causative factors
of dysplasia development. However, it remains possible that these
gene expression changes are simply part of the neoplastic transforma-
tion process. Future studies employing laser capture–microdissected
samples to establish the temporal relationship between change in
gene expression pattern and evolution of dysplasia may shed new
light on the cause–effect link between the two.
Among all these validated genes, Cebpd, Hoxa1, and Tp53 are the
ones upregulated in common in the two dysplasia panels. CCAAT/
enhancer binding proteins (C/EBP) are a highly conserved family of
basic leucine zipper transcription factors; six members (C/EBP-alpha
to -zeta) have been identified to date. This protein family plays a
critical role in cell proliferation, apoptosis, and inflammation, de-
pending on the cell type and specific physiological stress [31]. The pre-
cise functional role of C/EBP-delta, in particular, in normal prostate
biology and PCa remains poorly understood. Cebpd was shown to
be an androgen-repressed gene in the normal rat prostate [32,33], sup-
porting its role as an apoptotic mediator and/or a negative regulator of
cell proliferation. In a human androgen–dependent PCa xenograft, an-
drogen withdrawal, however, resulted in a decline in the expression of
C/EBP-delta [32]. Most published studies focus on the androgenic
regulation of C/EBP-delta; this is, therefore, the first report of the as-
sociation of estrogen-mediated upregulation of C/EBP-delta gene ex-
pression with the early phase of prostate carcinogenesis. A recent study
showed overexpression of C/EBP-beta, another member of the family,
in proliferative inflammatory atrophy in human prostate specimens,
suggesting its role in the inflammation-associated carcinogenesis in
the prostate [34]. In microarray data, we observed downregulation
of C/EBP-alpha (Cebpa) only in T + E2–treated dysplastic LPs, corrob-
orating its putative suppressive function in epithelial tumorigenesis
[35]. Together, these findings raise the possibility that an orchestrated
deregulation of C/EBP-family transcripts is involved in the pathogen-
esis of PCa in humans and rodents.
Homeobox gene (HOX ) is a family of transcription factors related
to growth and development. In rodents and humans, 39 members of
the HOX gene family have been assigned to four gene clusters (A–D)
and are numbered according to their expression along the anterior–
posterior axis. Hox13 was shown to be involved in cell differentia-
tion during normal prostate development [36], whereas upregula-
tions of HOXC have been observed in PCa cells [37,38]. Knockdown
of HOXC6 gene expression led to apoptosis of PCa cells [39], and
overexpression of the HOXC8 gene correlated with the loss of tumor
differentiation in human PCa [37]. Increased expression of the
HOXA1 transcript was detected in human clinical cervical cancer
samples and in several cervical cell lines compared with expression
in normal tissues [40,41]. Our data suggest that ectopic expres-
sion of Hoxa1 is related to the evolution of dysplasia in both LP
and VP and that the detailed roles of Hoxa1 in PCa require fur-
ther study.
Tp53 is a well-known tumor-suppressive transcription factor and
acts as a gatekeeper in signaling pathways involved in monitoring cel-
lular stress such as DNA damage and in the determination of con-
gruous responses (DNA repair, cell growth arrest, or apoptosis) to
specific physiological stress. Previous studies demonstrated that muta-
tion of Tp53 is not necessarily as late an event in prostate carcinogen-
esis as previously reported; it is also frequently found in high-grade
prostate intraepithelial neoplasia, a precursor lesion of PCa [42,43].
In this regard, we observed upregulation of Tp53 gene expression in
dysplastic rat prostate glands treated with sex hormone, implying a role
in early prostate tumorigenesis, but whether these glands express wild-
type or mutated Tp53 is not known. Alternatively, the induction of
Tp53 expression may be a compensatory response to cellular stress im-
posed by hormonal changes. We recently demonstrated that T + E2
treatment induced oxidative and nitrosative stress, accompanied by
DNA and protein damages, specifically in the LP, which is susceptible
to dysplasia/cancer induction [17].
Smad7, an inhibitory Smad, is rapidly induced by TGF-β, thereby
creating a negative feedback loop to a variety of TGF-β signaling
responses, including proliferation, differentiation, apoptosis, inflam-
mation, tissue remodeling, angiogenesis, and cell adhesion [44]. Dis-
ruption of the TGF-β signaling cascade by aberrant overexpression of
this negative modulator leads to increased tumorigenicity in colon can-
cer cells by blocking TGF-β–mediated growth inhibition and apop-
tosis [45]. In contrast, Smad7 has been shown to mediate apoptosis
induced by TGF-β in PCa cells [46], perhaps through crosstalking with
other cellular signaling cascades such as the p38 mitogen-activated pro-
tein kinase [47] and β-catenin/Wnt [48] pathways. In our study, up-
regulation of Smad7 in the dysplastic LP (also in the T + DES VP
microarray data) suggests perturbations of TGF-β feedback regulation
and thus the loss of balance between cell proliferation and apoptosis in
the early phase of prostate carcinogenesis.
A particularly interesting gene network found in the T + DES–
treated VP (Figure 4, B1 and B2) is related to E2 signaling. Members
include Src, Bcar1, and Plau. Src, a nonreceptor protein tyrosine ki-
nase, triggers the nongenomic estrogen signaling leading to activation
of ERK1/2 and cell proliferation in prostate epithelial cells [49,50]. It
remains to be determined if the downregulation of Src by DES rep-
resents a classic negative feedback loop. The Bcar1 interacts and
modulates Src activity [51]. An increase in Bcar1 gene expression,
as observed in the rat dysplastic VP, has also been reported in human
PCa [52]. The coordinated dysregulation of both Src (downregula-
tion) and Bcar1 (upregulation) may reflect a disruption of the Src-
dependent signaling pathway during the early development of PCa,
a notion further supported by the altered expression of Plau, a down-
stream target of Src [53]. Interestingly, both Bcar1 and Plau are in-
volved in cell survival and migration [54,55].
Our group recently demonstrated significant oxidative stress and in-
flammation in the T + E2–treated NBL rat LP [17,56]. The microarray
data show a relatively small fraction of genes related to redox homeo-
stasis and immune response, possibly due to inherent limitations of the
type and coverage size (about 3800 genes) of the array chips we se-
lected. However, T + E2 treatment was found to upregulate Klrb1 in
the LP. This gene, also known as NKR-P1A/CD161 in humans, en-
codes a natural killer (NK) cell C-type lectin–like receptor that regulates
NK cell functions. KLRB1 is expressed not only in NK cells but also in
immune cell types, such as T cells, monocytes, and dendritic cells [57].
Thus, it is likely that increased expression of Klrb1 in LP with T + E2
treatment is due to the infiltration of immune cells [17].
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The observation of a dramatic induction of Gpx3 in the VP dys-
plasia panel, as shown by microarray (>17-fold) and q-PCR (>70-
fold), is consistent with our previous report of a marked elevation
of GPX enzyme activity and lipid peroxidation in this lobe after
T + DES treatment [56]. Hence, the activation in this glutathione-
associated detoxification enzyme might be a response to hormone-
induced oxidative stress in the gland or represent a cytoprotective
mechanism, adapted by dysplastic cells, against oxidative insults.
An elevation of GPX3 expression, but not of GPX1 and GPX2,
was found in precancerous lesions of NKX3.1 mutant mouse pros-
tate [58]. Taken together, these findings suggest that GPX3 is specifi-
cally involved in early prostatic transformation that has a mechanistic
link to oxidative stress.
In summary, we showed that genes such as Cebpd, Tp53, and
Hoxa1 are at the core of disrupted biologic networks related to hormone-
induced dysplasia. Unbiased gene profiling clearly demonstrated differ-
ential susceptibility of the LP and VP to natural and xenoestrogen with
regard to alterations in gene expression and induction of dysplasia.
Our data suggest more functional divergence between DES and E2
in the disruption of prostatic functions than that previously suspected.
Methodologically, the combined utility of expression profiling and
gene network mapping provides an instrumental platform for tran-
scriptome studies.
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Table W1. Primers Used for Real-Time q-PCR.
Name Sequence Accession No. Tm Product Size (bp)
BCAR_UP1 CCAGGTTCCCAGGACATCTA NM_012931.1 59.92
BCAR_LP1 TGCTCACAGAAGGAGGAACA NM_012931.1 59.55 214
CEBPD_UP1 CAGGAGATGCAGCAGAAGC NM_013154.1 59.83
CEBPD_LP1 GTATCGGTCGTTCGGAGTCT NM_013154.1 59.17 198
Gpx3_UP1 ACCAATTTGGCAAACAGGAG NM_022525.2 59.97
Gpx3_LP1 TCAAAGAGCTGGAAATTAGGC NM_022525.2 59.18 110
Hoxa1_UP2 TTCTCCAGCGCAGACCTT NM_013075.1 59.66
Hoxa1_LP2 CCCACGTAGCCATACTCTCC NM_013075.1 59.57 84
KLRB1_UP1 TGGATAAACGGCTCGACTTT NM_173292.1 59.71
KLRB1_LP1 GCACTTTGTCCTGTGAGACG NM_173292.1 59.47 94
MAFB_UP2 AACGCGTCCAGCAGAAACAT NM_019316.1 59
MAFB_LP2 CTGCTCCACCTGCTGAATGA NM_019316.1 59 65
Nxph3_UP1 CTGCTGCTTCGTGTTCCTAGT NM_021679.1 52.38
Nxph3_LP1 CATCATGCTCAGGGTCCTC NM_021679.1 57.89 95
PLAU_UP1 AGCTGCCCAAAGAAATTCAA NM_013085.2 59.82
PLAU_LP1 TGGTGTCAGTATTGGCCTTTC NM_013085.2 59.99 106
SMAD7_UP1 AGAGGCTGTGTTGCTGTGAA NM_030858.1 59.62
SMAD7_LP1 GAGGAAGGTACAGCGTCTGG NM_030858.1 59.87 172
SRC_UP1 TGTGGAGCGGATGAACTATG NM_031977.1 59.67
SRC_LP1 TGATGGTGAACCTGCCATAC NM_031977.1 59.37 197
Thra_T1_UP1 ACAAGGCCACCGGTTATCAC NM_001017960.1 58
Thra_T1_LP1 GCGAAAGAAGCCCTTGCA NM_001017960.1 59 62
TP53_UP1 ACGTGCTCACACTGGCTAAA NM_030989.1 59.51
TP53_LP1 GGAGCTCGATGCTCATATCC NM_030989.1 59.76 189
Figure W1. Comparison of real-time q-PCR to microarray findings. Genes selected from (A) T + E2–induced LP dysplasia and (B) T +
DES–induced VP dysplasia panels.
Table W2. Genes Whose Expression Altered following T + E2 in the VPs with No Dysplastic Changes.
Gene Names Locus ID Symbol Fold Changes P FDR
T + E2 VP vs VP T + E2 VP vs VP T + E2 VP vs VP
Cell morphology
contactin-associated protein 1 84008 CNTNAP1 2.33 .0125 0.739395415
Cell to cell signaling and interaction
contactin-associated protein 1 84008 CNTNAP1 2.33 .0125 0.739395415
Cellular growth and proliferation
potassium voltage–gated channel, shaker-related subfamily, member 5 25470 KCNA5 −1.83 .0227 0.766365976
solute carrier family 12, member 2 83629 SLC12A2 1.57 .0142 0.739395415
Molecular transport
potassium voltage–gated channel, shaker-related subfamily, member 5 25470 KCNA5 −1.83 .0227 0.766365976
solute carrier family 12, member 2 83629 SLC12A2 1.57 .0142 0.739395415
Carbohydrate metabolism
lysozyme 25211 LYZ −1.55 .1027 0.916873843
Cellular assembly and organization
potassium voltage–gated channel, shaker-related subfamily, member 5 25470 KCNA5 −1.83 .0227 0.766365976
mucin 5, subtypes A and C, tracheobronchial/gastric 65188 MUC5AC 1.70 .0134 0.739395415
Small molecule biochemistry
ornithine decarboxylase antizyme inhibitor 58961 AZIN1 1.51 .0801 0.886144389
solute carrier family 12, member 2 83629 SLC12A2 1.57 .0142 0.739395415
lysozyme 25211 LYZ −1.55 .1027 0.916873843
Cell death
solute carrier family 12, member 2 83629 SLC12A2 1.57 .0142 0.739395415
SH3-domain kinase binding protein 1 84357 SH3KBP1 −1.56 .0011 0.443416906
Cellular function and maintenance
potassium voltage–gated channel, shaker-related subfamily, member 5 25470 KCNA5 −1.83 .0227 0.766365976
mucin 5, subtypes A and C, tracheobronchial/gastric 65188 MUC5AC 1.70 .0134 0.739395415
Cell signaling
major histocompatibility complex, class II, DM beta 294273 HLA-DMB 1.51 .0185 0.739395415
Drug metabolism
solute carrier family 12, member 2 83629 SLC12A2 1.57 .0142 0.739395415
Lipid metabolism
solute carrier family 12, member 2 83629 SLC12A2 1.57 .0142 0.739395415
We propose that these genes were not related to dysplasia development.
Genes were categorized according to their cellular functions (in bold and italics).
Table W3. Genes that Showed Altered Levels of Expression following T + DES in the LPs with No Dysplastic Changes.
Gene Names Locus ID Symbol Fold Changes P FDR
T + DES LP vs LP T + DES LP vs LP T + DES LP vs LP
Cell morphology
actin alpha cardiac 1 29275 ACTC1 2.30 .0000 0.000248913
actinin alpha 4 63836 ACTN4 −1.62 .0004 0.015327409
adducin 2 (beta) 24171 ADD2 −1.50 .0023 0.046831092
adrenergic receptor kinase, beta 1 25238 ADRBK1 −1.33 .0048 0.067126523
allograft inflammatory factor 1 29427 AIF1 −1.58 .0001 0.007642386
alanyl (membrane) aminopeptidase 81641 ANPEP 1.23 .0662 0.309192141
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
discs, large homolog 4 (Drosophila) 29495 DLG4 1.28 .0138 0.12501336
endothelial differentiation, lysophosphatidic acid
G-protein–coupled receptor, 2
116744 EDG2 1.50 .0006 0.020782669
ephrin A1 94268 EFNA1 −1.33 .0595 0.29465518
espin 56227 ESPN −1.65 .0004 0.015327409
growth hormone–releasing hormone 29446 GHRH 1.87 .0000 0.000562125
gap junction membrane channel protein alpha 3 79217 GJA3 −1.67 .0003 0.013918065
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
potassium inwardly rectifying channel, subfamily J,
member 10
29718 KCNJ10 1.57 .0002 0.011445829
NK6 transcription factor–related, locus 1 (Drosophila) 65193 NKX6-1 −1.31 .0144 0.128278942
protein kinase C and casein kinase substrate in
neurons 2
124461 PACSIN2 1.27 .0261 0.187905149
p21 (CDKN1A)–activated kinase1 29431 PAK1 1.99 .0000 0.001151782
paired box gene 6 25509 PAX6 −1.72 .0000 0.001014633
synuclein, gamma 64347 SNCG −1.83 .0014 0.034901656
Arg/Abl–interacting protein Arg BP2 114901 SORBS2 1.20 .0883 0.361834544
transition protein 2 24840 TNP2 −1.46 .0025 0.048139684
ubiquitin A-52 residue ribosomal protein fusion
product 1
64156 UBA52 −1.94 .0001 0.004893344
ubiquitin-conjugating enzyme E2I 25573 UBE2I 1.53 .0001 0.008104491
vesicle docking protein 56042 VDP −1.33 .0114 0.114843401
Cellular movement
actin, beta 81822 ACTB −1.34 .0132 0.121186877
actinin alpha 4 63836 ACTN4 −1.62 .0004 0.015327409
a disintegrin and metallopeptidase domain 1a 56777 ADAM1A −1.69 .0007 0.023296301
adrenergic receptor kinase, beta 1 25238 ADRBK1 −1.33 .0048 0.067126523
alanyl (membrane) aminopeptidase 81641 ANPEP 1.23 .0662 0.309192141
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
calponin 1 65204 CNN1 −1.04 .7878 0.930382649
cytotoxic T-lymphocyte–associated protein 4 63835 CTLA4 1.25 .0618 0.301897804
chemokine orphan receptor 1 84348 CXCR7 −1.57 .0008 0.025012801
discoidin domain receptor family, member 1 25678 DDR1 −1.75 .0000 0.002145778
defensin beta 1 83687 DEFB1 −1.15 .1095 0.409029443
endothelial differentiation, lysophosphatidic acid
G-protein–coupled receptor, 2
116744 EDG2 1.50 .0006 0.020782669
ephrin A1 94268 EFNA1 −1.33 .0595 0.29465518
coagulation factor X 29243 F10 −1.80 .0004 0.016178933
proprotein convertase subtilisin/kexin type 3 54281 FURIN −1.46 .0026 0.048296067
guanine nucleotide binding protein, alpha z subunit 25740 GNAZ 1.46 .0041 0.060465974
glycogen synthase kinase 3 alpha 50686 GSK3A −1.27 .0048 0.066546045
guanylate cyclase 1, soluble, alpha 3 25201 GUCY1A3 2.07 .0000 0.000248913
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
mucosal vascular addressin cell adhesion molecule 1 54266 MADCAM1 −1.53 .0051 0.068231134
metastasis-associated 1 64520 MTA1 −1.40 .0225 0.172625732
NK6 transcription factor–related, locus 1 (Drosophila) 65193 NKX6-1 −1.31 .0144 0.128278942
nuclear receptor subfamily 4, group A, member 3 58853 NR4A3 −1.51 .0383 0.23317558
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
paired box gene 6 25509 PAX6 −1.72 .0000 0.001014633
polymeric immunoglobulin receptor 25046 PIGR −1.35 .0066 0.080018243
protein kinase N1 29355 PKN1 1.51 .0001 0.005817694
phospholipase C, beta 3 29322 PLCB3 −1.54 .0020 0.043467607
prion protein 24686 PRNP −1.33 .1183 0.42614185
protein tyrosine phosphatase, receptor type, F 360406 PTPRF −1.44 .0029 0.050810807
retinoic acid receptor, alpha 24705 RARA −1.45 .0003 0.0125346
slit homolog 3 (Drosophila) 83467 SLIT3 1.51 .0005 0.017227903
synuclein, gamma 64347 SNCG −1.83 .0014 0.034901656
ventral anterior homeobox 1 64571 VAX1 −1.52 .0001 0.007642386
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide
29753 YWHAE −1.54 .0014 0.034901656
Gene Names Locus ID Symbol Fold Changes P FDR
T + DES LP vs LP T + DES LP vs LP T + DES LP vs LP
Cell signaling
adrenergic receptor, alpha 2c 24175 ADRA2C −1.35 .0729 0.3262758
adrenergic receptor kinase, beta 1 25238 ADRBK1 −1.33 .0048 0.067126523
calcineurin binding protein 1 94165 CABIN1 1.47 .0000 0.004028913
calcium channel, voltage-dependent, T type, alpha 1
G subunit
29717 CACNA1G −1.50 .0002 0.011161422
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
endothelial differentiation, lysophosphatidic acid
G-protein–coupled receptor, 2
116744 EDG2 1.50 .0006 0.020782669
ephrin A1 94268 EFNA1 −1.33 .0595 0.29465518
gamma-aminobutyric acid A receptor, rho 1 29694 GABRR1 1.87 .0000 0.000345513
growth hormone–releasing hormone 29446 GHRH 1.87 .0000 0.000562125
guanine nucleotide binding protein, beta 3 60449 GNB3 1.68 .0000 0.002364708
glutamate receptor, ionotropic, kainate 3 298521 GRIK3 2.06 .0000 2.51e−06
G protein–coupled receptor 24 83567 MCHR1 −1.52 .0002 0.00962618
protein kinase C and casein kinase substrate in
neurons 2
124461 PACSIN2 1.27 .0261 0.187905149
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
fertility protein SP22 117287 PARK7 −1.22 .2198 0.566510451
phosphodiesterase 4A 25638 PDE4A −1.55 .0011 0.030023803
protein kinase N1 29355 PKN1 1.51 .0001 0.005817694
Arg/Abl–interacting protein Arg BP2 114901 SORBS2 1.20 .0883 0.361834544
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide
29753 YWHAE −1.54 .0014 0.034901656
Cellular growth and proliferation
allograft inflammatory factor 1 29427 AIF1 −1.58 .0001 0.007642386
calcium channel, voltage-dependent, T type, alpha 1
G subunit
29717 CACNA1G −1.50 .0002 0.011161422
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
CD63 antigen 29186 CD63 −1.10 .4195 0.737185743
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
Cbp/p300–interacting transactivator with Glu/Asp–rich
carboxy-terminal domain 1
64466 CITED1 −1.53 .0019 0.042644963
calponin 1 65204 CNN1 −1.04 .7878 0.930382649
cytotoxic T-lymphocyte–associated protein 4 63835 CTLA4 1.25 .0618 0.301897804
chemokine orphan receptor 1 84348 CXCR7 −1.57 .0008 0.025012801
discoidin domain receptor family, member 1 25678 DDR1 −1.75 .0000 0.002145778
ddx5 gene 287765 DDX5 −1.27 .1781 0.520336467
endothelial differentiation, lysophosphatidic acid
G-protein–coupled receptor, 2
116744 EDG2 1.50 .0006 0.020782669
ephrin A1 94268 EFNA1 −1.33 .0595 0.29465518
F-box only protein 2 85273 FBXO2 −1.42 .0115 0.114843401
growth hormone–releasing hormone receptor 25321 GHRHR −1.59 .0255 0.186284598
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
metastasis-associated 1 64520 MTA1 −1.40 .0225 0.172625732
nuclear receptor subfamily 4, group A, member 3 58853 NR4A3 −1.51 .0383 0.23317558
paired box gene 6 25509 PAX6 −1.72 .0000 0.001014633
polymeric immunoglobulin receptor 25046 PIGR −1.35 .0066 0.080018243
protein tyrosine phosphatase, receptor type, F 360406 PTPRF −1.44 .0029 0.050810807
retinoic acid receptor, alpha 24705 RARA −1.45 .0003 0.0125346
synuclein, gamma 64347 SNCG −1.83 .0014 0.034901656
ventral anterior homeobox 1 64571 VAX1 −1.52 .0001 0.007642386
zinc finger protein of the cerebellum 1 64618 ZIC1 −1.54 .0002 0.00960067
Cell to cell signaling and interaction
a disintegrin and metallopeptidase domain 1a 56777 ADAM1A −1.69 .0007 0.023296301
adrenergic receptor, alpha 2c 24175 ADRA2C −1.35 .0729 0.3262758
amelogenin X chromosome 29160 AMELX −1.71 .0000 0.000345513
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
cytotoxic T-lymphocyte–associated protein 4 63835 CTLA4 1.25 .0618 0.301897804
discoidin domain receptor family, member 1 25678 DDR1 −1.75 .0000 0.002145778
discs, large homolog 4 (Drosophila) 29495 DLG4 1.28 .0138 0.12501336
ephrin A1 94268 EFNA1 −1.33 .0595 0.29465518
coagulation factor X 29243 F10 −1.80 .0004 0.016178933
fibrinogen, gamma polypeptide 24367 FGG −1.79 .0067 0.080887122
proprotein convertase subtilisin/kexin type 3 54281 FURIN −1.46 .0026 0.048296067
gap junction membrane channel protein alpha 3 79217 GJA3 −1.67 .0003 0.013918065
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
mucosal vascular addressin cell adhesion molecule 1 54266 MADCAM1 −1.53 .0051 0.068231134
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
polymeric immunoglobulin receptor 25046 PIGR −1.35 .0066 0.080018243
Table W3. (continued )
Gene Names Locus ID Symbol Fold Changes P FDR
T + DES LP vs LP T + DES LP vs LP T + DES LP vs LP
proteasome (prosome, macropain) 28 subunit, beta 29614 PSME2 1.40 .0008 0.025480573
retinoic acid receptor, alpha 24705 RARA −1.45 .0003 0.0125346
Rhesus blood group CE and D 60414 RHD −1.45 .0030 0.050810807
ubiquitin A-52 residue ribosomal protein fusion
product 1
64156 UBA52 −1.94 .0001 0.004893344
ubiquitin-conjugating enzyme E2I 25573 UBE2I 1.53 .0001 0.008104491
ventral anterior homeobox 1 64571 VAX1 −1.52 .0001 0.007642386
Cellular function and maintenance
blocked early in transport 1 homolog (S. cerevisiae) like 54400 BET1L −1.31 .0707 0.321228605
calcineurin binding protein 1 94165 CABIN1 1.47 .0000 0.004028913
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
cytotoxic T-lymphocyte–associated protein 4 63835 CTLA4 1.25 .0618 0.301897804
ephrin A1 94268 EFNA1 −1.33 .0595 0.29465518
fibrinogen, gamma polypeptide 24367 FGG −1.79 .0067 0.080887122
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
protein kinase C and casein kinase substrate in
neurons 2
124461 PACSIN2 1.27 .0261 0.187905149
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
protein tyrosine phosphatase, receptor type, F 360406 PTPRF −1.44 .0029 0.050810807
retinoic acid receptor, alpha 24705 RARA −1.45 .0003 0.0125346
ubiquitin-conjugating enzyme E2I 25573 UBE2I 1.53 .0001 0.008104491
vesicle docking protein 56042 VDP −1.33 .0114 0.114843401
Cellular assembly and organization
actin, beta 81822 ACTB −1.34 .0132 0.121186877
actin alpha cardiac 1 29275 ACTC1 2.30 .0000 0.000248913
actinin alpha 4 63836 ACTN4 −1.62 .0004 0.015327409
a disintegrin and metallopeptidase domain 1a 56777 ADAM1A −1.69 .0007 0.023296301
ADP-ribosylation factor 1 64310 ARF1 −1.51 .0042 0.06161559
blocked early in transport 1 homolog (S. cerevisiae) like 54400 BET1L −1.31 .0707 0.321228605
calcineurin binding protein 1 94165 CABIN1 1.47 .0000 0.004028913
calpain 3 29155 CAPN3 −1.06 .6514 0.868611888
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
cytotoxic T-lymphocyte–associated protein 4 63835 CTLA4 1.25 .0618 0.301897804
discs, large homolog 4 (Drosophila) 29495 DLG4 1.28 .0138 0.12501336
phenylalkylamine Ca2+ antagonist (emopamil)
binding protein
117278 EBP −1.24 .1023 0.394501794
endothelial differentiation, lysophosphatidic acid
G-protein–coupled receptor, 2
116744 EDG2 1.50 .0006 0.020782669
ephrin A1 94268 EFNA1 −1.33 .0595 0.29465518
espin 56227 ESPN −1.65 .0004 0.015327409
fibrinogen, gamma polypeptide 24367 FGG −1.79 .0067 0.080887122
protein kinase C and casein kinase substrate in
neurons 2
124461 PACSIN2 1.27 .0261 0.187905149
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
paired box gene 6 25509 PAX6 −1.72 .0000 0.001014633
protein tyrosine phosphatase, receptor type, F 360406 PTPRF −1.44 .0029 0.050810807
Rhesus blood group CE and D 60414 RHD −1.45 .0030 0.050810807
Arg/Abl–interacting protein Arg BP2 114901 SORBS2 1.20 .0883 0.361834544
transition protein 2 24840 TNP2 −1.46 .0025 0.048139684
ubiquitin-conjugating enzyme E2I 25573 UBE2I 1.53 .0001 0.008104491
ventral anterior homeobox 1 64571 VAX1 −1.52 .0001 0.007642386
vesicle docking protein 56042 VDP −1.33 .0114 0.114843401
Cellular development
adducin 2 (beta) 24171 ADD2 −1.50 .0023 0.046831092
adrenergic receptor kinase, beta 1 25238 ADRBK1 −1.33 .0048 0.067126523
allograft inflammatory factor 1 29427 AIF1 −1.58 .0001 0.007642386
alanyl (membrane) aminopeptidase 81641 ANPEP 1.23 .0662 0.309192141
calcitonin/calcitonin–related polypeptide, alpha 24241 CALCA 1.57 .0002 0.00960067
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
cytotoxic T-lymphocyte–associated protein 4 63835 CTLA4 1.25 .0618 0.301897804
discoidin domain receptor family, member 1 25678 DDR1 −1.75 .0000 0.002145778
phenylalkylamine Ca2+ antagonist (emopamil)
binding protein
117278 EBP −1.24 .1023 0.394501794
endothelial differentiation, lysophosphatidic acid
G-protein–coupled receptor, 2
116744 EDG2 1.50 .0006 0.020782669
ephrin A1 94268 EFNA1 −1.33 .0595 0.29465518
eukaryotic translation initiation factor 2B, subunit
4 delta
117019 EIF2B4 −1.32 .0626 0.302985912
Table W3. (continued )
Gene Names Locus ID Symbol Fold Changes P FDR
T + DES LP vs LP T + DES LP vs LP T + DES LP vs LP
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
potassium inwardly rectifying channel, subfamily J,
member 10
29718 KCNJ10 1.57 .0002 0.011445829
neurogenic differentiation 2 54276 NEUROD2 −1.47 .0457 0.259241663
NK6 transcription factor–related, locus 1 (Drosophila) 65193 NKX6-1 −1.31 .0144 0.128278942
nuclear receptor subfamily 4, group A, member 3 58853 NR4A3 −1.51 .0383 0.23317558
platelet-activating factor acetylhydrolase, isoform 1b,
alpha1 subunit
114113 PAFAH1B3 −1.59 .0007 0.021362381
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
paired box gene 6 25509 PAX6 −1.72 .0000 0.001014633
prion protein 24686 PRNP −1.33 .1183 0.42614185
retinoic acid receptor, alpha 24705 RARA −1.45 .0003 0.0125346
SNF-related kinase 170837 SNRK −1.68 .0002 0.01079459
zinc finger protein of the cerebellum 1 64618 ZIC1 −1.54 .0002 0.00960067
Vitamin and mineral metabolism
adrenergic receptor kinase, beta 1 25238 ADRBK1 −1.33 .0048 0.067126523
calcium channel, voltage-dependent, T type, alpha 1
G subunit
29717 CACNA1G −1.50 .0002 0.011161422
growth hormone–releasing hormone 29446 GHRH 1.87 .0000 0.000562125
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide
29753 YWHAE −1.54 .0014 0.034901656
gamma-glutamyl hydrolase 25455 GGH 1.05 .6924 0.88871634
Nucleic acid metabolism
growth hormone–releasing hormone 29446 GHRH 1.87 .0000 0.000562125
G protein–coupled receptor 24 83567 MCHR1 −1.52 .0002 0.00962618
phosphodiesterase 4A 25638 PDE4A −1.55 .0011 0.030023803
heat shock 10 kDa protein 1 25462 HSPE1 −1.53 .0302 0.202134203
Cell cycle
allograft inflammatory factor 1 29427 AIF1 −1.58 .0001 0.007642386
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
cytotoxic T-lymphocyte–associated protein 4 63835 CTLA4 1.25 .0618 0.301897804
aspartyl-tRNA synthetase 116483 DARS −1.43 .0353 0.221986221
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
nuclear receptor subfamily 4, group A, member 3 58853 NR4A3 −1.51 .0383 0.23317558
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
paired box gene 6 25509 PAX6 −1.72 .0000 0.001014633
protein tyrosine phosphatase, receptor type, F 360406 PTPRF −1.44 .0029 0.050810807
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide
29753 YWHAE −1.54 .0014 0.034901656
Cell death
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
NK6 transcription factor–related, locus 1 (Drosophila) 65193 NKX6-1 −1.31 .0144 0.128278942
ornithine decarboxylase antizyme 1 25502 OAZ1 −1.61 .0040 0.059747718
prolyl 4-hydroxylase, beta polypeptide 25506 P4HB −1.29 .0491 0.266073897
prion protein 24686 PRNP −1.33 .1183 0.42614185
retinoic acid receptor, alpha 24705 RARA −1.45 .0003 0.0125346
Cellular compromise
adducin 2 (beta) 24171 ADD2 −1.50 .0023 0.046831092
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
calponin 1 65204 CNN1 −1.04 .7878 0.930382649
cytotoxic T-lymphocyte–associated protein 4 63835 CTLA4 1.25 .0618 0.301897804
ephrin A1 94268 EFNA1 −1.33 .0595 0.29465518
G-protein–coupled receptor 37 117549 GPR37 −1.24 .0689 0.316311201
heat shock 10 kDa protein 1 25462 HSPE1 −1.53 .0302 0.202134203
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
potassium inwardly rectifying channel, subfamily J,
member 10
29718 KCNJ10 1.57 .0002 0.011445829
mucosal vascular addressin cell adhesion molecule 1 54266 MADCAM1 −1.53 .0051 0.068231134
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
prion protein 24686 PRNP −1.33 .1183 0.42614185
synuclein, gamma 64347 SNCG −1.83 .0014 0.034901656
Arg/Abl–interacting protein Arg BP2 114901 SORBS2 1.20 .0883 0.361834544
Gene expression
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
Cbp/p300–interacting transactivator with Glu/Asp–rich
carboxy-terminal domain 1
64466 CITED1 −1.53 .0019 0.042644963
ddx5 gene 287765 DDX5 −1.27 .1781 0.520336467
glucocorticoid modulatory element binding protein 2 83635 GMEB2 1.44 .0013 0.033527564
hairy and enhancer of split 2 (Drosophila) 29567 HES2 −1.66 .0001 0.008055371
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
Table W3. (continued )
Gene Names Locus ID Symbol Fold Changes P FDR
T + DES LP vs LP T + DES LP vs LP T + DES LP vs LP
interleukin enhancer binding factor 3 84472 ILF3 −1.45 .0041 0.060465974
neurogenic differentiation 2 54276 NEUROD2 −1.47 .0457 0.259241663
nuclear factor I/C 29228 NFIC −1.54 .0000 0.001390745
nuclear receptor subfamily 3, group C, member 2 25672 NR3C2 1.57 .0025 0.048296067
nuclear receptor subfamily 4, group A, member 3 58853 NR4A3 −1.51 .0383 0.23317558
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
paired box gene 6 25509 PAX6 −1.72 .0000 0.001014633
paired box gene 8 81819 PAX8 −1.50 .0027 0.049209986
protein kinase N1 29355 PKN1 1.51 .0001 0.005817694
prion protein 24686 PRNP −1.33 .1183 0.42614185
retinoic acid receptor, alpha 24705 RARA −1.45 .0003 0.0125346
retinoblastoma binding protein 7 83712 RBBP7 −1.15 .2769 0.626562643
suppression of tumorigenicity 18 266680 ST18 1.16 .3190 0.656804744
telomerase-associated protein 1 64523 TEP1 −1.53 .0024 0.047008762
ubiquitin A-52 residue ribosomal protein fusion
product 1
64156 UBA52 −1.94 .0001 0.004893344
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide
29753 YWHAE −1.54 .0014 0.034901656
Amino acid metabolism
adrenergic receptor kinase, beta 1 25238 ADRBK1 −1.33 .0048 0.067126523
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
glycine cleavage system protein H (aminomethyl carrier) 171133 GCSH −1.43 .0131 0.120934801
gamma-glutamyl hydrolase 25455 GGH 1.05 .6924 0.88871634
glycogen synthase kinase 3 alpha 50686 GSK3A −1.27 .0048 0.066546045
prolyl 4-hydroxylase, beta polypeptide 25506 P4HB −1.29 .0491 0.266073897
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
paired box gene 8 81819 PAX8 −1.50 .0027 0.049209986
protein kinase N1 29355 PKN1 1.51 .0001 0.005817694
Post–translational modification
adrenergic receptor kinase, beta 1 25238 ADRBK1 −1.33 .0048 0.067126523
glycine cleavage system protein H (aminomethyl carrier) 171133 GCSH −1.43 .0131 0.120934801
glycogen synthase kinase 3 alpha 50686 GSK3A −1.27 .0048 0.066546045
prolyl 4-hydroxylase, beta polypeptide 25506 P4HB −1.29 .0491 0.266073897
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
protein kinase N1 29355 PKN1 1.51 .0001 0.005817694
Carbohydrate metabolism
apolipoprotein A-V 140638 APOA5 −1.43 .0022 0.045371928
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
growth hormone–releasing hormone 29446 GHRH 1.87 .0000 0.000562125
guanine nucleotide binding protein, alpha z subunit 25740 GNAZ 1.46 .0041 0.060465974
neuromedin B receptor 25264 NMBR 1.66 .0005 0.017227903
prion protein 24686 PRNP −1.33 .1183 0.42614185
Cellular response to therapeutics
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
DNA replication, recombination, and repair
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
prion protein 24686 PRNP −1.33 .1183 0.42614185
Drug metabolism
apolipoprotein A-V 140638 APOA5 −1.43 .0022 0.045371928
phenylalkylamine Ca2+ antagonist (emopamil)
binding protein
117278 EBP −1.24 .1023 0.394501794
gamma-glutamyl hydrolase 25455 GGH 1.05 .6924 0.88871634
growth hormone–releasing hormone 29446 GHRH 1.87 .0000 0.000562125
insulin-like 6 50546 IL1RAP 1.56 .0002 0.01079459
fertility protein SP22 117287 PARK7 −1.22 .2198 0.566510451
prion protein 24686 PRNP −1.33 .1183 0.42614185
Energy production
heat shock 10 kDa protein 1 25462 HSPE1 −1.53 .0302 0.202134203
Pyruvate carboxylase 25104 PC −1.68 .0005 0.017227903
Lipid metabolism
adrenergic receptor, alpha 2c 24175 ADRA2C −1.35 .0729 0.3262758
adrenergic receptor kinase, beta 1 25238 ADRBK1 −1.33 .0048 0.067126523
apolipoprotein A-V 140638 APOA5 −1.43 .0022 0.045371928
apolipoprotein C-I 25292 APOC1 −1.45 .0040 0.060048723
ADP-ribosylation factor 1 64310 ARF1 −1.51 .0042 0.06161559
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
cytochrome P450, 4a12 266674 CYP4A22 1.29 .0127 0.118852704
phenylalkylamine Ca2+ antagonist (emopamil)
binding protein
117278 EBP −1.24 .1023 0.394501794
coagulation factor X 29243 F10 −1.80 .0004 0.016178933
growth hormone–releasing hormone 29446 GHRH 1.87 .0000 0.000562125
Table W3. (continued )
Gene Names Locus ID Symbol Fold Changes P FDR
T + DES LP vs LP T + DES LP vs LP T + DES LP vs LP
growth hormone–releasing hormone receptor 25321 GHRHR −1.59 .0255 0.186284598
CCA2 protein 246211 HSD3B7 −1.14 .2909 0.639015905
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
platelet-activating factor acetylhydrolase, isoform 1b,
alpha1 subunit
114113 PAFAH1B3 −1.59 .0007 0.021362381
phosphatidylinositol-4-phosphate 5-kinase, type II, alpha 116723 PIP5K2A −1.54 .0028 0.050001834
Molecular transport
adducin 2 (beta) 24171 ADD2 −1.50 .0023 0.046831092
apolipoprotein A-V 140638 APOA5 −1.43 .0022 0.045371928
apolipoprotein C-I 25292 APOC1 −1.45 .0040 0.060048723
ADP-ribosylation factor 1 64310 ARF1 −1.51 .0042 0.06161559
ADP-ribosylation factor 3 140940 ARF3 −1.73 .0015 0.035552435
ATPase, H+ transporting, V1 subunit F 116664 ATP6V1F 1.82 .0000 0.002117528
calcium channel, voltage-dependent, T type, alpha 1
G subunit
29717 CACNA1G −1.50 .0002 0.011161422
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
gamma-glutamyl hydrolase 25455 GGH 1.05 .6924 0.88871634
growth hormone–releasing hormone 29446 GHRH 1.87 .0000 0.000562125
guanine nucleotide binding protein, alpha z subunit 25740 GNAZ 1.46 .0041 0.060465974
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
potassium voltage–gated channel, Shaw-related subfamily,
member 1
25327 KCNC1 1.88 .0000 0.001278795
potassium voltage–gated channel, Shaw-related subfamily,
member 3
117101 KCNC3 1.28 .0499 0.267188376
potassium inwardly rectifying channel, subfamily J,
member 10
29718 KCNJ10 1.57 .0002 0.011445829
potassium large conductance calcium–activated channel,
subfamily M, beta member 1
29747 KCNMB1 1.45 .0016 0.037292397
G protein–coupled receptor 24 83567 MCHR1 −1.52 .0002 0.00962618
neuromedin B receptor 25264 NMBR 1.66 .0005 0.017227903
nuclear receptor subfamily 3, group C, member 2 25672 NR3C2 1.57 .0025 0.048296067
ornithine decarboxylase antizyme 1 25502 OAZ1 −1.61 .0040 0.059747718
fertility protein SP22 117287 PARK7 −1.22 .2198 0.566510451
paired box gene 8 81819 PAX8 −1.50 .0027 0.049209986
phosphodiesterase 4A 25638 PDE4A −1.55 .0011 0.030023803
phosphatidylinositol-4-phosphate 5-kinase, type II, alpha 116723 PIP5K2A −1.54 .0028 0.050001834
phospholipase C, beta 3 29322 PLCB3 −1.54 .0020 0.043467607
transmembrane 4 superfamily member 11 64364 PLLP −1.89 .0001 0.007928851
RAB10, member RAS oncogene family 50993 RAB10 −1.26 .1155 0.421950743
vesicle docking protein 56042 VDP −1.33 .0114 0.114843401
protein kinase, lysine-deficient 1 116477 WNK1 −1.23 .0401 0.239581758
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, epsilon polypeptide
29753 YWHAE −1.54 .0014 0.034901656
Protein degradation
alanyl (membrane) aminopeptidase 81641 ANPEP 1.23 .0662 0.309192141
calpain 3 29155 CAPN3 −1.06 .6514 0.868611888
F-box only protein 2 85273 FBXO2 −1.42 .0115 0.114843401
proprotein convertase subtilisin/kexin type 3 54281 FURIN −1.46 .0026 0.048296067
ubiquitin A-52 residue ribosomal protein fusion
product 1
64156 UBA52 −1.94 .0001 0.004893344
Protein synthesis
ubiquitin A-52 residue ribosomal protein fusion
product 1
64156 UBA52 −1.94 .0001 0.004893344
alanyl (membrane) aminopeptidase 81641 ANPEP 1.23 .0662 0.309192141
proprotein convertase subtilisin/kexin type 3 54281 FURIN −1.46 .0026 0.048296067
F-box only protein 2 85273 FBXO2 −1.42 .0115 0.114843401
calpain 3 29155 CAPN3 −1.06 .6514 0.868611888
eukaryotic translation initiation factor 2B, subunit
4 delta
117019 EIF2B4 −1.32 .0626 0.302985912
aspartyl-tRNA synthetase 116483 DARS −1.43 .0353 0.221986221
ribosomal protein L41 124440 RPL41 1.11 .5675 0.833181167
ribosomal protein S27 94266 RPS27 −1.90 .0001 0.00504934
ribosomal protein L22 81768 RPL22 −1.28 .1257 0.438278138
ribosomal protein L24 64307 RPL24 −1.21 .2217 0.567754925
ribosomal protein L4 64302 RPL4 −1.42 .0425 0.248528309
Protein trafficking
ADP-ribosylation factor 1 64310 ARF1 −1.51 .0042 0.06161559
cofilin 1 29271 CFL1 −1.39 .0163 0.137582819
vesicle docking protein 56042 VDP −1.33 .0114 0.114843401
ADP-ribosylation factor 3 140940 ARF3 −1.73 .0015 0.035552435
RAB10, member RAS oncogene family 50993 RAB10 −1.26 .1155 0.421950743
Table W3. (continued )
Gene Names Locus ID Symbol Fold Changes P FDR
T + DES LP vs LP T + DES LP vs LP T + DES LP vs LP
protein tyrosine phosphatase, receptor type, F 360406 PTPRF −1.44 .0029 0.050810807
RNA damage and repair
telomerase-associated protein 1 64523 TEP1 −1.53 .0024 0.047008762
RNA post–transcriptional modification
telomerase-associated protein 1 64523 TEP1 −1.53 .0024 0.047008762
prion protein 24686 PRNP −1.33 .1183 0.42614185
Small molecule biochemistry
glycine cleavage system protein H (aminomethyl carrier) 171133 GCSH −1.43 .0131 0.120934801
neuromedin B receptor 25264 NMBR 1.66 .0005 0.017227903
guanine nucleotide binding protein, alpha z subunit 25740 GNAZ 1.46 .0041 0.060465974
nuclear receptor subfamily 3, group C, member 2 25672 NR3C2 1.57 .0025 0.048296067
apolipoprotein C-I 25292 APOC1 −1.45 .0040 0.060048723
apolipoprotein A-V 140638 APOA5 −1.43 .0022 0.045371928
platelet-activating factor acetylhydrolase, isoform 1b,
alpha1 subunit
114113 PAFAH1B3 −1.59 .0007 0.021362381
prion protein 24686 PRNP −1.33 .1183 0.42614185
ornithine decarboxylase antizyme 1 25502 OAZ1 −1.61 .0040 0.059747718
phosphatidylinositol-4-phosphate 5-kinase, type II, alpha 116723 PIP5K2A −1.54 .0028 0.050001834
CCA2 protein 246211 HSD3B7 −1.14 .2909 0.639015905
interleukin 5 24497 IL5 −1.52 .0526 0.275768333
aspartyl-tRNA synthetase 116483 DARS −1.43 .0353 0.221986221
adrenergic receptor, alpha 2c 24175 ADRA2C −1.35 .0729 0.3262758
cytochrome P450, 4a12 266674 CYP4A22 1.29 .0127 0.118852704
coagulation factor X 29243 F10 −1.80 .0004 0.016178933
heat shock 10 kDa protein 1 25462 HSPE1 −1.53 .0302 0.202134203
paired box gene 8 81819 PAX8 −1.50 .0027 0.049209986
phospholipase C, beta 3 29322 PLCB3 −1.54 .0020 0.043467607
CCAAT/enhancer binding protein (C/EBP), alpha 24252 CEBPA −1.53 .0095 0.101978652
gamma-glutamyl hydrolase 25455 GGH 1.05 .6924 0.88871634
prolyl 4-hydroxylase, beta polypeptide 25506 P4HB −1.29 .0491 0.266073897
fertility protein SP22 117287 PARK7 −1.22 .2198 0.566510451
phenylalkylamine Ca2+ antagonist (emopamil)
binding protein
117278 EBP −1.24 .1023 0.394501794
ADP-ribosylation factor 1 64310 ARF1 −1.51 .0042 0.06161559
acetylcholinesterase 83817 ACHE −1.61 .0009 0.026111212
adrenergic receptor kinase, beta 1 25238 ADRBK1 −1.33 .0048 0.067126523
small inducible cytokine A4 116637 CCL4 1.50 .0017 0.038035447
growth hormone–releasing hormone 29446 GHRH 1.87 .0000 0.000562125
glycogen synthase kinase 3 alpha 50686 GSK3A −1.27 .0048 0.066546045
insulin-like 6 50546 IL1RAP 1.56 .0002 0.01079459
G protein–coupled receptor 24 83567 MCHR1 −1.52 .0002 0.00962618
p21 (CDKN1A)–activated kinase 1 29431 PAK1 1.99 .0000 0.001151782
phosphodiesterase 4A 25638 PDE4A −1.55 .0011 0.030023803
protein kinase N1 29355 PKN1 1.51 .0001 0.005817694
sulfotransferase family, cytosolic, 1C, member 2 171072 SULT1C2 1.40 .0066 0.080018243
Others/unclassified
acetylcholinesterase 83817 ACHE −1.61 .0009 0.026111212
A kinase (PRKA) anchor protein 14 60332 AKAP14 1.75 .0000 0.000345513
ADP-ribosylation factor 5 79117 ARF5 1.18 .1270 0.441864518
ATP synthase, H+ transporting, mitochondrial F1
complex, O subunit
192241 ATP5O −1.21 .1429 0.469959614
barrier to autointegration factor 1 114087 BANF1 1.94 .0000 0.000627148
complement component 1, q subcomponent,
beta polypeptide
29687 C1QB 1.33 .0055 0.071144019
calcium channel, voltage-dependent, alpha 1I subunit 56827 CACNA1I −1.49 .0013 0.033306477
calcitonin/calcitonin–related polypeptide, alpha 24241 CALCA 1.57 .0002 0.00960067
steroid-sensitive gene 1 64387 CCDC80 −1.68 .0010 0.027773162
caudal type homeobox 1 171042 CDX1(includesEG:171042) −1.38 .0779 0.339542448
chloride channel Kb 79430 CLCNKB 1.34 .0202 0.162131033
cytochrome c oxidase subunit IV isoform 1 29445 COX4I1 2.01 .0000 0.000345513
cleavage and polyadenylation–specific factor 4 252943 CPSF4 −1.47 .0363 0.225382474
upstream of NRAS 117180 CSDE1 −1.48 .0027 0.049042265
casein kinase 1, alpha 1 113927 CSNK1A1 −1.48 .0010 0.027890942
chondroitin sulfate proteoglycan 5 50568 CSPG5 1.42 .0130 0.12061056
cytochrome P450, family 2, subfamily c, polypeptide 7 29298 CYP2C9 1.52 .0030 0.050810807
dipeptidase 1 (renal) 94199 DPEP1 −1.15 .2356 0.588068112
putative pheromone receptor Go-VN13C 286986 EG665255 −1.30 .0159 0.136403128
carboxylesterase 1 29225 ES22 −1.53 .0138 0.12501336
Ena-vasodilator–stimulated phosphoprotein 79115 EVL −1.48 .0006 0.020979393
Fas apoptotic inhibitory molecule 2 246274 FAIM2 1.74 .0000 0.000313065
gap junction membrane channel protein beta 4 117055 GJB4 −1.62 .0026 0.048592575
galectin-related interfiber protein 117130 GRIFIN −1.14 .1826 0.525238789
Table W3. (continued )
Gene Names Locus ID Symbol Fold Changes P FDR
T + DES LP vs LP T + DES LP vs LP T + DES LP vs LP
general transcription factor IIa 2 83828 GTF2A2 −1.52 .0018 0.040904546
3-hydroxyisobutyrate dehydrogenase 63938 HIBADH −1.63 .0092 0.099998918
neural visinin–like Ca2+–binding protein type 3 50871 HPCAL1 −1.39 .0014 0.034901656
hydroxy-delta-5-steroid dehydrogenase, 3 beta-andosteroid
delta-isomerase 1
29632 HSD3B2(includesEG:3284) 1.59 .0132 0.121186877
interferon, alpha-inducible protein 27–like 170512 IFI27 −1.33 .0082 0.092474595
potassium voltage–gated channel, shaker-related subfamily,
beta member 1
29737 KCNAB1 −1.47 .0009 0.026111212
potassium channel, subfamily K, member 9 84429 KCNK9 2.54 .0000 3.18e−05
preoptic regulatory factor-2 286903 KIAA1688 −1.86 .0000 0.001310057
epididymal retinoic acid–binding protein 29552 LCN5 −1.33 .1328 0.451496546
leptin receptor overlapping transcript 56766 LEPROT 1.23 .0800 0.344030409
Alpha-1,6-mannosyl-glycoprotein2-beta-
N-acetylglucosaminyltransferase
94273 MGAT2 −1.49 .0003 0.013861053
membrane protein, palmitoylated 2 (MAGUK p55
subfamily member 2)
85275 MPP2 −1.54 .0013 0.033527564
membrane protein, palmitoylated 3 (MAGUK p55
subfamily member 3)
114202 MPP3 −1.78 .0000 0.00238426
myosin ID 25485 MYO1D −1.86 .0000 0.002259596
myosin IE 25484 MYO1E −1.49 .0045 0.063968949
N-acetyltransferase 8 (camello-like) 64570 NAT8 1.60 .0005 0.018001605
nuclear factor I/X 81524 NFIX −1.40 .0020 0.043375551
phosphodiesterase 4C, cAMP-specific 290646 PDE4C −1.56 .0015 0.035439407
phosphofructokinase, muscle 65152 PFKM 1.41 .0036 0.05720289
phospholipase C, delta 4 140693 PLCD4 1.06 .5888 0.839859691
pregnancy upregulated nonubiquitously expressed
CaM kinase
29660 PNCK 1.82 .0000 0.004388703
protein phosphatase 1, regulatory subunit 10 65045 PPP1R10 −1.45 .0110 0.112064665
protein phosphatase 3, catalytic subunit, beta isoform 24675 PPP3CB −1.05 .6773 0.882757484
prolactin-like protein L 171556 PRLPL 1.11 .3118 0.65353078
PR-Vbeta1 498341 PR-Vbeta1 2.20 .0000 3.18e−05
Carcinoembryonic antigen gene family (CGM3) 24256 PSG18 1.61 .0001 0.00831627
quinoid dihydropteridine reductase 64192 QDPR −1.70 .0343 0.218922533
rabaptin 5 54190 RABEP1 −1.46 .0204 0.162411357
RASD family, member 2 171099 RASD2 1.13 .2983 0.645268138
Ras association (RalGDS/AF-6) domain family 5 54355 RASSF5 1.15 .1864 0.528802493
ribosomal protein L10A 81729 RPL10A(includesEG:81729) −1.40 .0364 0.225382474
ribosomal protein L27 64306 RPL27 −1.33 .0245 0.181311206
ribosomal protein L28 64638 RPL28 −1.65 .0005 0.019279688
ribosomal protein L29 29283 RPL29(includesEG:29283) −1.66 .0011 0.029296571
ribosomal protein S12 65139 RPS12 1.55 .0012 0.0316706
ribosomal protein S15 29285 RPS15 −1.37 .0212 0.16563314
ribosomal protein S21 81775 RPS21 −1.04 .7860 0.92990797
ribosomal protein S27a 81777 RPS27A 1.09 .5567 0.826186782
ribosomal protein S9 81772 RPS9 1.46 .0018 0.039884914
spondin 1 64456 SPON1 1.46 .0006 0.021028906
sulfotransferase family 4A, member 1 58953 SULT4A1 −1.45 .0008 0.025012801
synaptogyrin 2 89815 SYNGR2 −1.47 .0016 0.038035447
tachykinin receptor 2 25007 TACR2 1.27 .0327 0.212543742
testis-enhanced gene transcript 24822 TEGT −1.63 .0004 0.015893027
translocase of inner mitochondrial membrane
22 homolog (yeast)
79463 TIMM22 −1.48 .0054 0.07023214
transmembrane protein with EGF-like and two
follistatin-like domains 1
63845 TMEFF1 −1.85 .0059 0.075505805
translocase of outerm itochondrial membrane
20 homolog (yeast)
266601 TOMM20 1.18 .1323 0.451237424
vesicle-associated membrane protein 2 24803 VAMP2 2.23 .0000 0.002259596
zinc finger protein 111 170849 ZNF227 −1.69 .0006 0.019354079
We propose that these genes was unlikely to be related to dysplasia induction.
Genes were categorized according to their cellular functions (in bold and italics).
Table W3. (continued )
Table W4. T + E2–Insensitive Panel: Genes that Showed No Significant Changes in Their Expres-
sion Levels in the LPs or/and VPs following T + E2 Treatment Relative to Their Respective Un-
treated Controls.
Gene Names Locus ID Symbol
Cellular movement
arrestin, beta 2 25388 ARRB2
androgen receptor 24208 AR
signal transducer and activator of transcription 5A 24918 STAT5A
interleukin 7 25647 IL7
chemokine (C–C motif ) ligand 3 25542 CCL3
neuropilin 2 81527 NRP2
midkine 81517 MDK
v-myc myelocytomatosis viral–related oncogene,
neuroblastoma-derived (avian) (mapped)
298894 MYCN
peptide YY (mapped) 287730 PYY
cyclin-dependent kinase 5 140908 CDK5
protein tyrosine phosphatase, nonreceptor type 12 117255 PTPN12
calcium and integrin binding 1 (calmyrin) 81823 CIB1
neogenin 81735 NEO1
mitogen-activated protein kinase 14 81649 MAPK14
activated leukocyte cell adhesion molecule 79559 ALCAM
matrix metalloproteinase 16 65205 MMP16
complexin 1 64832 CPLX1
rhoB gene 64373 RHOB
legumain 63865 LGMN
matrix metallopeptidase 8 63849 MMP8
cd86 antigen 56822 CD86
lectin, galactose binding, soluble 1 56646 LGALS1
neuroblastoma, suppression of tumorigenicity 1 50594 NBL1
phosphatase and tensin homolog 50557 PTEN
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
collagen, type 1, alpha 1 29393 COL1A1
calpain, small subunit 1 29156 CAPNS1
neurofibromatosis 2 25744 NF2
synaptotagmin 3 25731 SYT3
integrin beta 4 25724 ITGB4
Inhibitor of DNA binding 2, dominant negative
helix–loop–helix protein
25587 ID2
peptidylprolyl isomerase A 25518 PPIA
paired box gene 6 25509 PAX6
intercellular adhesion molecule 1 25464 ICAM1
glial cell line–derived neurotrophic factor family
receptor alpha 1
25454 GFRA1
arrestin, beta 1 25387 ARRB1
cytochrome P450, family 19, subfamily a, polypeptide 1 25147 CYP19A1
CD24 antigen 25145 CD24
tropomyosin 4 24852 TPM4
ATP-binding cassette, subfamily C (CFTR/MRP),
member 1
24565 ABCC1
insulin-like growth factor 1 24482 IGF1
Cell death
arrestin, beta 2 25388 ARRB2
androgen receptor 24208 AR
signal transducer and activator of transcription 5A 24918 STAT5A
interleukin 7 25647 IL7
chemokine (C–C motif ) ligand 3 25542 CCL3
midkine 81517 MDK
v-myc myelocytomatosis viral–related oncogene,
neuroblastoma-derived (avian) (mapped)
298894 MYCN
peptide YY (mapped) 287730 PYY
cyclin-dependent kinase 5 140908 CDK5
calcium and integrin binding 1 (calmyrin) 81823 CIB1
mitogen-activated protein kinase 14 81649 MAPK14
rhoB gene 64373 RHOB
matrix metallopeptidase 8 63849 MMP8
cd86 antigen 56822 CD86
lectin, galactose binding, soluble 1 56646 LGALS1
phosphatase and tensin homolog 50557 PTEN
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
calpain, small subunit 1 29156 CAPNS1
neurofibromatosis 2 25744 NF2
integrin beta 4 25724 ITGB4
Inhibitor of DNA binding 2, dominant negative
helix–loop–helix protein
25587 ID2
Gene Names Locus ID Symbol
peptidylprolyl isomerase A 25518 PPIA
paired box gene 6 25509 PAX6
intercellular adhesion molecule 1 25464 ICAM1
glial cell line–derived neurotrophic factor family
receptor alpha 1
25454 GFRA1
cytochrome P450, family 19, subfamily a, polypeptide 1 25147 CYP19A1
CD24 antigen 25145 CD24
ATP-binding cassette, subfamily C (CFTR/MRP),
member 1
24565 ABCC1
insulin-like growth factor 1 24482 IGF1
metallothionein 1a 24567 MT1E
metallothionein 3 117038 MT3
structure-specific recognition protein 1 81785 SSRP1
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
calcitonin receptor 116506 CALCR
epithelial membrane protein 3 81505 EMP3
persephin 25525 PSPN
HLA-B–associated transcript 3 94342 BAT3
cyclin-dependent kinase 2 362817 CDK2
cell division cycle 25 homolog A (S. cerevisiae) 171102 CDC25A
protein tyrosine phosphatase, nonreceptor type 23 117552 PTPN23
peroxiredoxin 1 117254 PRDX1
thyroid hormone receptor interactor 10 116717 TRIP10
A kinase (PRKA) anchor protein 1 114124 AKAP1
calbindin 1 83839 CALB1
wild-type p53–induced gene 1 64394 ZMAT3
unc-5 homolog A (C. elegans) 60629 UNC5A
transglutaminase 1 60335 TGM1
mitogen-activated protein kinase 13 29513 MAPK13
glutathione S-transferase, pi 2 29438 GSTP1
fatty acid amide hydrolase 29347 FAAH
prothymosin alpha 29222 PTMA
stannin 29140 SNN
monoamine oxidase B 25750 MAOB
prostaglandin D2 synthase 25526 PTGDS
glypican 3 25236 GPC3
cytochrome P450, family 2, subfamily e, polypeptide 1 25086 CYP2E1
ATPase, Cu2+ transporting, beta polypeptide 24218 ATP7B
Cell cycle
androgen receptor 24208 AR
signal transducer and activator of transcription 5A 24918 STAT5A
interleukin 7 25647 IL7
chemokine (C–C motif ) ligand 3 25542 CCL3
midkine 81517 MDK
v-myc myelocytomatosis viral–related oncogene,
neuroblastoma-derived (avian) (mapped)
298894 MYCN
mitogen-activated protein kinase 14 81649 MAPK14
rhoB gene 64373 RHOB
lectin, galactose binding, soluble 1 56646 LGALS1
phosphatase and tensin homolog 50557 PTEN
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
neurofibromatosis 2 25744 NF2
Inhibitor of DNA binding 2, dominant negative
helix–loop–helix protein
25587 ID2
paired box gene 6 25509 PAX6
insulin-like growth factor 1 24482 IGF1
structure-specific recognition protein 1 81785 SSRP1
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
calcitonin receptor 116506 CALCR
cyclin-dependent kinase 2 362817 CDK2
cell division cycle 25 homolog A (S. cerevisiae) 171102 CDC25A
prothymosin alpha 29222 PTMA
collagen, type 1, alpha 1 29393 COL1A1
arrestin, beta 1 25387 ARRB1
high mobility group box transcription factor 1 27080 HBP1
septin 9 83788 SEPT9
Cell morphology
androgen receptor 24208 AR
interleukin 7 25647 IL7
chemokine (C–C motif ) ligand 3 25542 CCL3
v-myc myelocytomatosis viral–related oncogene,
neuroblastoma-derived (avian) (mapped)
298894 MYCN
mitogen-activated protein kinase 14 81649 MAPK14
Table W4. (continued )
Gene Names Locus ID Symbol
rhoB gene 64373 RHOB
lectin, galactose binding, soluble 1 56646 LGALS1
phosphatase and tensin homolog 50557 PTEN
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
Inhibitor of DNA binding 2, dominant negative
helix–loop–helix protein
25587 ID2
paired box gene 6 25509 PAX6
insulin-like growth factor 1 24482 IGF1
cyclin-dependent kinase 2 362817 CDK2
cell division cycle 25 homolog A (S. cerevisiae) 171102 CDC25A
collagen, type 1, alpha 1 29393 COL1A1
high mobility group box transcription factor 1 27080 HBP1
arrestin, beta 2 25388 ARRB2
cyclin-dependent kinase 5 140908 CDK5
calcium and integrin binding 1 (calmyrin) 81823 CIB1
integrin beta 4 25724 ITGB4
intercellular adhesion molecule 1 25464 ICAM1
glial cell line–derived neurotrophic factor family
receptor alpha 1
25454 GFRA1
cytochrome P450, family 19, subfamily a, polypeptide 1 25147 CYP19A1
CD24 antigen 25145 CD24
protein tyrosine phosphatase, nonreceptor type 23 117552 PTPN23
peroxiredoxin 1 117254 PRDX1
calbindin 1 83839 CALB1
mitogen-activated protein kinase 13 29513 MAPK13
prostaglandin D2 synthase 25526 PTGDS
protein tyrosine phosphatase, nonreceptor type 12 117255 PTPN12
inositol polyphosphate phosphatase–like 1 65038 INPPL1
RAS protein–specific guanine nucleotide–releasing
factor 1
192213 RASGRF1
procollagen, type I, alpha 2 84352 COL1A2
ERM-binding phosphoprotein 59114 SLC9A3R1
clathrin, heavy polypeptide (Hc) 54241 CLTC
Cellular growth and proliferation
androgen receptor 24208 AR
interleukin 7 25647 IL7
chemokine (C–C motif ) ligand 3 25542 CCL3
v-myc myelocytomatosis viral–related oncogene,
neuroblastoma-derived (avian) (mapped)
298894 MYCN
mitogen-activated protein kinase 14 81649 MAPK14
rhoB gene 64373 RHOB
lectin, galactose binding, soluble 1 56646 LGALS1
phosphatase and tensin homolog 50557 PTEN
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
Inhibitor of DNA binding 2, dominant negative
helix–loop–helix protein
25587 ID2
paired box gene 6 25509 PAX6
insulin-like growth factor 1 24482 IGF1
cyclin-dependent kinase 2 362817 CDK2
cell division cycle 25 homolog A (S. cerevisiae) 171102 CDC25A
collagen, type 1, alpha 1 29393 COL1A1
arrestin, beta 2 25388 ARRB2
cyclin-dependent kinase 5 140908 CDK5
integrin beta 4 25724 ITGB4
intercellular adhesion molecule 1 25464 ICAM1
glial cell line–derived neurotrophic factor family
receptor alpha 1
25454 GFRA1
cytochrome P450, family 19, subfamily a, polypeptide 1 25147 CYP19A1
CD24 antigen 25145 CD24
peroxiredoxin 1 117254 PRDX1
inositol polyphosphate phosphatase–like 1 65038 INPPL1
RAS protein–specific guanine nucleotide–releasing
factor 1
192213 RASGRF1
ERM-binding phosphoprotein 59114 SLC9A3R1
clathrin, heavy polypeptide (Hc) 54241 CLTC
signal transducer and activator of transcription 5A 24918 STAT5A
midkine 81517 MDK
neurofibromatosis 2 25744 NF2
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
calcitonin receptor 116506 CALCR
prothymosin alpha 29222 PTMA
peptide YY (mapped) 287730 PYY
Gene Names Locus ID Symbol
cd86 antigen 56822 CD86
calpain, small subunit 1 29156 CAPNS1
peptidylprolyl isomerase A 25518 PPIA
metallothionein 1a 24567 MT1E
metallothionein 3 117038 MT3
epithelial membrane protein 3 81505 EMP3
wild-type p53–induced gene 1 64394 ZMAT3
glutathione S-transferase, pi 2 29438 GSTP1
glypican 3 25236 GPC3
neogenin 81735 NEO1
legumain 63865 LGMN
beta-microseminoprotein 29311 MSMB
solute carrier family 7 (cationic amino acid
transporter, y+ system), member 7
83509 SLC7A7
nuclear factor I/X 81524 NFIX
insulin-induced gene 1 64194 INSIG1
FXYD domain–containing ion transport
regulator 1
58971 FXYD1
fibroblast growth factor 17 29368 FGF17
solute carrier family 4, member 1 24779 SLC4A1
Molecular transport
chemokine (C–C motif ) ligand 3 25542 CCL3
phosphatase and tensin homolog 50557 PTEN
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
insulin-like growth factor 1 24482 IGF1
arrestin, beta 2 25388 ARRB2
intercellular adhesion molecule 1 25464 ICAM1
peroxiredoxin 1 117254 PRDX1
inositol polyphosphate phosphatase–like 1 65038 INPPL1
ERM-binding phosphoprotein 59114 SLC9A3R1
signal transducer and activator of transcription 5A 24918 STAT5A
calcitonin receptor 116506 CALCR
peptidylprolyl isomerase A 25518 PPIA
insulin-induced gene 1 64194 INSIG1
solute carrier family 4, member 1 24779 SLC4A1
calbindin 1 83839 CALB1
arrestin, beta 1 25387 ARRB1
ATP-binding cassette, subfamily C (CFTR/MRP),
member 1
24565 ABCC1
A kinase (PRKA) anchor protein 1 114124 AKAP1
cytochrome P450, family 2, subfamily e, polypeptide 1 25086 CYP2E1
ATPase, Cu2+ transporting, beta polypeptide 24218 ATP7B
carbonic anhydrase 2 54231 CA2
solute carrier family 32 (GABA vesicular
transporter), member 1
83612 SLC32A1
potassium inwardly rectifying channel, subfamily J,
member 11
83535 KCNJ11
solute carrier family 30 (zinc transporter),
member 2
25362 SLC30A2
sodium channel, nonvoltage-gated, type I,
alpha polypeptide
25122 SCNN1A
potassium voltage–gated channel, Shab-related
subfamily, member 2
117105 KCNB2
nuclear receptor subfamily 1, group I, member 2 84385 NR1I2
transient receptor potential cation channel,
subfamily C, member 2
64573 TRPC2
hyperpolarization-activated, cyclic
nucleotide–gated K+ 4
59266 HCN4
solute carrier family 14 (urea transporter), member 1 54301 SLC14A1
potassium intermediate/small conductance
calcium–activated channel, subfamily N, member 3
54263 KCNN3
solute carrier family 6 (neurotransmitter
transporter, betaine/GABA), member 12
50676 SLC6A12
potassium inwardly rectifying channel, subfamily J,
member 3
50599 KCNJ3
DNA replication, recombination, and repair
phosphatase and tensin homolog 50557 PTEN
insulin-like growth factor 1 24482 IGF1
arrestin, beta 2 25388 ARRB2
inositol polyphosphate phosphatase–like 1 65038 INPPL1
arrestin, beta 1 25387 ARRB1
cyclin-dependent kinase 2 362817 CDK2
cell division cycle 25 homolog A (S. cerevisiae) 171102 CDC25A
Table W4. (continued ) Table W4. (continued )
Gene Names Locus ID Symbol
Cellular assembly and organization
phosphatase and tensin homolog 50557 PTEN
insulin-like growth factor 1 24482 IGF1
cyclin-dependent kinase 2 362817 CDK2
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
intercellular adhesion molecule 1 25464 ICAM1
A kinase (PRKA) anchor protein 1 114124 AKAP1
mitogen-activated protein kinase 14 81649 MAPK14
rhoB gene 64373 RHOB
cyclin-dependent kinase 5 140908 CDK5
glial cell line–derived neurotrophic factor family
receptor alpha 1
25454 GFRA1
CD24 antigen 25145 CD24
peptide YY (mapped) 287730 PYY
thyroid hormone receptor interactor 10 116717 TRIP10
complexin 1 64832 CPLX1
synaptotagmin 3 25731 SYT3
LIM motif–containing protein kinase 2 29524 LIMK2
coronin, actin-binding protein, 1B 29474 CORO1B
synapsin III 29130 SYN3
Cell signaling
insulin-like growth factor 1 24482 IGF1
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
intercellular adhesion molecule 1 25464 ICAM1
A kinase (PRKA) anchor protein 1 114124 AKAP1
cyclin-dependent kinase 5 140908 CDK5
arrestin, beta 2 25388 ARRB2
arrestin, beta 1 25387 ARRB1
chemokine (C–C motif ) ligand 3 25542 CCL3
ERM-binding phosphoprotein 59114 SLC9A3R1
calcitonin receptor 116506 CALCR
peptidylprolyl isomerase A 25518 PPIA
calbindin 1 83839 CALB1
potassium inwardly rectifying channel, subfamily J,
member 11
83535 KCNJ11
transient receptor potential cation channel,
subfamily C, member 2
64573 TRPC2
homeodomain interacting protein kinase 3 83617 HIPK3
Nucleic acid metabolism
insulin-like growth factor 1 24482 IGF1
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
intercellular adhesion molecule 1 25464 ICAM1
arrestin, beta 2 25388 ARRB2
arrestin, beta 1 25387 ARRB1
chemokine (C–C motif ) ligand 3 25542 CCL3
calcitonin receptor 116506 CALCR
Small molecule biochemistry
insulin-like growth factor 1 24482 IGF1
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
intercellular adhesion molecule 1 25464 ICAM1
arrestin, beta 2 25388 ARRB2
arrestin, beta 1 25387 ARRB1
chemokine (C–C motif ) ligand 3 25542 CCL3
calcitonin receptor 116506 CALCR
cyclin-dependent kinase 5 140908 CDK5
homeodomain interacting protein kinase 3 83617 HIPK3
phosphatase and tensin homolog 50557 PTEN
cyclin-dependent kinase 2 362817 CDK2
mitogen-activated protein kinase 14 81649 MAPK14
LIM motif–containing protein kinase 2 29524 LIMK2
inositol polyphosphate phosphatase–like 1 65038 INPPL1
peroxiredoxin 1 117254 PRDX1
signal transducer and activator of transcription 5A 24918 STAT5A
insulin-induced gene 1 64194 INSIG1
solute carrier family 4, member 1 24779 SLC4A1
ATP-binding cassette, subfamily C (CFTR/MRP),
member 1
24565 ABCC1
ATPase, Cu2+ transporting, beta polypeptide 24218 ATP7B
carbonic anhydrase 2 54231 CA2
Table W4. (continued )
Gene Names Locus ID Symbol
solute carrier family 32 (GABA vesicular
transporter), member 1
83612 SLC32A1
nuclear receptor subfamily 1, group I, member 2 84385 NR1I2
solute carrier family 6 (neurotransmitter
transporter, betaine/GABA), member 12
50676 SLC6A12
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
metallothionein 1a 24567 MT1E
metallothionein 3 117038 MT3
neogenin 81735 NEO1
protein tyrosine phosphatase, nonreceptor type 12 117255 PTPN12
transglutaminase 1 60335 TGM1
fatty acid amide hydrolase 29347 FAAH
monoamine oxidase B 25750 MAOB
phosphorylase kinase, gamma 2 (testis) 140671 PHKG2
solute carrier family 17 (sodium-dependent
inorganic phosphate cotransporter), member 7
116638 SLC17A7
Rab geranylgeranyl transferase, a subunit 58983 RABGGTA
Cellular development
insulin-like growth factor 1 24482 IGF1
intercellular adhesion molecule 1 25464 ICAM1
arrestin, beta 2 25388 ARRB2
chemokine (C–C motif ) ligand 3 25542 CCL3
calcitonin receptor 116506 CALCR
cyclin-dependent kinase 5 140908 CDK5
phosphatase and tensin homolog 50557 PTEN
cyclin-dependent kinase 2 362817 CDK2
mitogen-activated protein kinase 14 81649 MAPK14
LIM motif–containing protein kinase 2 29524 LIMK2
signal transducer and activator of transcription 5A 24918 STAT5A
carbonic anhydrase 2 54231 CA2
protein tyrosine phosphatase, nonreceptor type 12 117255 PTPN12
transglutaminase 1 60335 TGM1
peptidylprolyl isomerase A 25518 PPIA
rhoB gene 64373 RHOB
glial cell line–derived neurotrophic factor family
receptor alpha 1
25454 GFRA1
CD24 antigen 25145 CD24
androgen receptor 24208 AR
interleukin 7 25647 IL7
lectin, galactose binding, soluble 1 56646 LGALS1
Inhibitor of DNA binding 2, dominant negative
helix–loop–helix protein
25587 ID2
paired box gene 6 25509 PAX6
integrin beta 4 25724 ITGB4
cytochrome P450, family 19, subfamily a,
polypeptide 1
25147 CYP19A1
prothymosin alpha 29222 PTMA
cd86 antigen 56822 CD86
high mobility group box transcription factor 1 27080 HBP1
calcium and integrin binding 1 (calmyrin) 81823 CIB1
neuropilin 2 81527 NRP2
Notch gene homolog 3 (Drosophila) 56761 NOTCH3
Post–Translational Modification
insulin-like growth factor 1 24482 IGF1
arrestin, beta 2 25388 ARRB2
chemokine (C–C motif ) ligand 3 25542 CCL3
cyclin-dependent kinase 5 140908 CDK5
phosphatase and tensin homolog 50557 PTEN
cyclin-dependent kinase 2 362817 CDK2
mitogen-activated protein kinase 14 81649 MAPK14
LIM motif–containing protein kinase 2 29524 LIMK2
protein tyrosine phosphatase, nonreceptor type 12 117255 PTPN12
transglutaminase 1 60335 TGM1
peptidylprolyl isomerase A 25518 PPIA
interleukin 7 25647 IL7
lectin, galactose binding, soluble 1 56646 LGALS1
homeodomain interacting protein kinase 3 83617 HIPK3
peroxiredoxin 1 117254 PRDX1
nuclear receptor subfamily 1, group I, member 2 84385 NR1I2
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
phosphorylase kinase, gamma 2 (testis) 140671 PHKG2
Rab geranylgeranyl transferase, a subunit 58983 RABGGTA
gamma-glutamyl carboxylase 81716 GGCX
Table W4. (continued )
Gene Names Locus ID Symbol
Cellular function and maintenance
insulin-like growth factor 1 24482 IGF1
chemokine (C–C motif ) ligand 3 25542 CCL3
cyclin-dependent kinase 5 140908 CDK5
phosphatase and tensin homolog 50557 PTEN
mitogen-activated protein kinase 14 81649 MAPK14
interleukin 7 25647 IL7
peroxiredoxin 1 117254 PRDX1
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
intercellular adhesion molecule 1 25464 ICAM1
CD24 antigen 25145 CD24
prothymosin alpha 29222 PTMA
high mobility group box transcription factor 1 27080 HBP1
ATP-binding cassette, subfamily C (CFTR/MRP),
member 1
24565 ABCC1
peptide YY (mapped) 287730 PYY
complexin 1 64832 CPLX1
synaptotagmin 3 25731 SYT3
v-myc myelocytomatosis viral–related oncogene,
neuroblastoma-derived (avian) (mapped)
298894 MYCN
Rsec5 protein 171455 EXOC2
Cell to cell signaling and interaction
insulin-like growth factor 1 24482 IGF1
chemokine (C–C motif ) ligand 3 25542 CCL3
cyclin-dependent kinase 5 140908 CDK5
phosphatase and tensin homolog 50557 PTEN
mitogen-activated protein kinase 14 81649 MAPK14
interleukin 7 25647 IL7
intercellular adhesion molecule 1 25464 ICAM1
CD24 antigen 25145 CD24
prothymosin alpha 29222 PTMA
peptide YY (mapped) 287730 PYY
complexin 1 64832 CPLX1
v-myc myelocytomatosis viral–related oncogene,
neuroblastoma-derived (avian) (mapped)
298894 MYCN
arrestin, beta 2 25388 ARRB2
lectin, galactose binding, soluble 1 56646 LGALS1
signal transducer and activator of transcription 5A 24918 STAT5A
glial cell line–derived neurotrophic factor family
receptor alpha 1
25454 GFRA1
androgen receptor 24208 AR
Inhibitor of DNA binding 2, dominant negative
helix–loop–helix protein
25587 ID2
integrin beta 4 25724 ITGB4
cd86 antigen 56822 CD86
calcium and integrin binding 1 (calmyrin) 81823 CIB1
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
inositol polyphosphate phosphatase–like 1 65038 INPPL1
solute carrier family 4, member 1 24779 SLC4A1
neogenin 81735 NEO1
solute carrier family 17 (sodium-dependent
inorganic phosphate cotransporter), member 7
116638 SLC17A7
calbindin 1 83839 CALB1
hyperpolarization-activated, cyclic nucleotide–
gated K+ 4
59266 HCN4
potassium intermediate/small conductance
calcium–activated channel, subfamily N, member 3
54263 KCNN3
RAS protein–specific guanine nucleotide–releasing
factor 1
192213 RASGRF1
midkine 81517 MDK
glypican 3 25236 GPC3
activated leukocyte cell adhesion molecule 79559 ALCAM
tropomodulin 2 58814 TMOD2
cholinergic receptor, nicotinic, beta polypeptide 2
(neuronal)
54239 CHRNB2
Gene expression
insulin-like growth factor 1 24482 IGF1
phosphatase and tensin homolog 50557 PTEN
mitogen-activated protein kinase 14 81649 MAPK14
prothymosin alpha 29222 PTMA
v-myc myelocytomatosis viral–related oncogene,
neuroblastoma-derived (avian) (mapped)
298894 MYCN
lectin, galactose binding, soluble 1 56646 LGALS1
Table W4. (continued )
Gene Names Locus ID Symbol
signal transducer and activator of transcription 5A 24918 STAT5A
androgen receptor 24208 AR
Inhibitor of DNA binding 2, dominant negative
helix–loop–helix protein
25587 ID2
integrin beta 4 25724 ITGB4
cd86 antigen 56822 CD86
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
inositol polyphosphate phosphatase–like 1 65038 INPPL1
neogenin 81735 NEO1
RAS protein–specific guanine nucleotide–releasing
factor 1
192213 RASGRF1
cyclin-dependent kinase 2 362817 CDK2
nuclear receptor subfamily 1, group I, member 2 84385 NR1I2
rhoB gene 64373 RHOB
paired box gene 6 25509 PAX6
cytochrome P450, family 19, subfamily a, polypeptide 1 25147 CYP19A1
Notch gene homolog 3 (Drosophila) 56761 NOTCH3
glutathione S-transferase, pi 2 29438 GSTP1
nuclear factor I/X 81524 NFIX
FXYD domain–containing ion transport regulator 1 58971 FXYD1
mitogen-activated protein kinase 13 29513 MAPK13
structure-specific recognition protein 1 81785 SSRP1
proteasome (prosome, macropain) 26S subunit,
non-ATPase, 9
161475 PSMD9
basic transcription element binding protein 1 117560 KLF9
Kruppel-like factor 15 85497 KLF15
general transcription factor IIa 2 83828 GTF2A2
Sjogren syndrome antigen B 81783 SSB
fatty acid binding protein 4, adipocyte 79451 FABP4
PDZ and LIM domain 1 (elfin) 54133 PDLIM1
Amino acid metabolism
insulin-like growth factor 1 24482 IGF1
phosphatase and tensin homolog 50557 PTEN
mitogen-activated protein kinase 14 81649 MAPK14
cyclin-dependent kinase 2 362817 CDK2
nuclear receptor subfamily 1, group I, member 2 84385 NR1I2
cyclin-dependent kinase 5 140908 CDK5
solute carrier family 4, member 1 24779 SLC4A1
solute carrier family 17 (sodium-dependent
inorganic phosphate cotransporter), member 7
116638 SLC17A7
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
LIM motif–containing protein kinase 2 29524 LIMK2
protein tyrosine phosphatase, nonreceptor type 12 117255 PTPN12
transglutaminase 1 60335 TGM1
homeodomain interacting protein kinase 3 83617 HIPK3
phosphorylase kinase, gamma 2 (testis) 140671 PHKG2
Rab geranylgeranyl transferase, a subunit 58983 RABGGTA
solute carrier family 32 (GABA vesicular transporter),
member 1
83612 SLC32A1
Lipid metabolism
insulin-like growth factor 1 24482 IGF1
phosphatase and tensin homolog 50557 PTEN
nuclear receptor subfamily 1, group I, member 2 84385 NR1I2
transglutaminase 1 60335 TGM1
signal transducer and activator of transcription 5A 24918 STAT5A
inositol polyphosphate phosphatase–like 1 65038 INPPL1
neogenin 81735 NEO1
arrestin, beta 2 25388 ARRB2
ATP-binding cassette, subfamily C (CFTR/MRP),
member 1
24565 ABCC1
arrestin, beta 1 25387 ARRB1
insulin-induced gene 1 64194 INSIG1
fatty acid amide hydrolase 29347 FAAH
Cellular compromise
ATP-binding cassette, subfamily C (CFTR/MRP),
member 1
24565 ABCC1
fatty acid amide hydrolase 29347 FAAH
mitogen-activated protein kinase 14 81649 MAPK14
RAS protein–specific guanine nucleotide–releasing
factor 1
192213 RASGRF1
peroxiredoxin 1 117254 PRDX1
metallothionein 1a 24567 MT1E
metallothionein 3 117038 MT3
Table W4. (continued )
Gene Names Locus ID Symbol
cytochrome P450, family 2, subfamily e, polypeptide 1 25086 CYP2E1
Vitamin and mineral metabolism
insulin-like growth factor 1 24482 IGF1
endothelial differentiation sphingolipid
G-protein–coupled receptor 1
29733 EDG1
chemokine (C–C motif ) ligand 3 25542 CCL3
intercellular adhesion molecule 1 25464 ICAM1
calbindin 1 83839 CALB1
peptidylprolyl isomerase A 25518 PPIA
calcitonin receptor 116506 CALCR
A kinase (PRKA) anchor protein 1 114124 AKAP1
ERM-binding phosphoprotein 59114 SLC9A3R1
potassium inwardly rectifying channel, subfamily J,
member 11
83535 KCNJ11
transient receptor potential cation channel,
subfamily C, member 2
64573 TRPC2
Drug metabolism
ATPase, Cu2+ transporting, beta polypeptide 24218 ATP7B
Others/unclassified
solute carrier family 5 (sodium-dependent vitamin
transporter), member 6
170551 SLC5A6
solute carrier family 28 (sodium-coupled
nucleoside transporter), member 2
60423 SLC28A2
selenoprotein P, plasma, 1 29360 SEPP1
etoile, Sam68-like protein SLM-2 64015 KHDRBS3
ubc2e ubiquitin–conjugating enzyme 641452 UBE2D2
RT1 class II, locus Da 294269 HLA-DRA
similar to Leydig cell tumor 10 kDa protein 288913 C19ORF53
voltage-gated channel like 1 266760 VGCNL1
guanine nucleotide binding protein (G protein),
gamma 8 subunit
245986 GNG8
membrane and microfilament–associated protein p58 207121 RGD:727794
seminal vesicle secretion 3 192239 SEMG2
methionine adenosyltransferase II, alpha 171347 MAT2A
LIM homeobox protein 5 124451 LHX5
CD52 antigen 117054 CD52
CEA-related cell adhesion molecule 9 116711 CEACAM9
ubiquilin 1 114590 UBQLN1
carboxylesterase 3 113902 CES1
synaptogyrin 2 89815 SYNGR2
low-density lipoprotein receptor–related protein 3 89787 LRP3
MAD homolog 9 (Drosophila) 85435 SMAD9
protein kinase C, delta binding protein 85332 PRKCDBP
nucleobindin 1 84595 NUCB1
RAB6A, member RAS oncogene family 84379 RAB6A
ATPase, class II, type 9A 84011 ATP9A
NSFL1 (p97) cofactor (p47) 83809 NSFL1C
tripartite motif protein 3 83616 TRIM3
discoidin domain receptor family, member 2 83573 DDR2
cadherin EGF LAG seven-pass G-type receptor 2 83465 CELSR2
5-hydroxytryptamine (serotonin) receptor 5B 79247 HTR5B
ADP-ribosylation factor 4 79120 ARF4
olfactory receptor 226 65140 OR6A2
probasin 54193 PBSN
mini chromosome maintenance deficient 6 (S. cerevisiae) 29685 MCM6
argininosuccinate synthetase 25698 ASS1
sialyltransferase 8 C 25547 ST8SIA3
apolipoprotein B editing complex 1 25383 APOBEC1
lysozyme 25211 LYZ
secretoglobin, family 2A, member 1 25010 PSBP1
phosphoglucomutase 1 24645 PGM1
filaggrin 24641 FLG
malate dehydrogenase 1, NAD (soluble) 24551 MDH1
Genes were categorized according to their cellular functions (in bold and italics).
Table W4. (continued )
Table W5. T + DES–Insensitive Panel: Genes Whose Expression Levels Were Not Significantly
Changed in the LPs or/and VPs following T + DES Treatment Relative to Their Respective Un-
treated Controls.
Gene Names Locus ID Symbol
Amino acid metabolism
solute carrier family 32 (GABA vesicular transporter),
member 1
83612 SLC32A1
Carbohydrate metabolism
protein kinase, AMP-activated, alpha 2
catalytic subunit
78975 PRKAA2
inositol polyphosphate phosphatase–like 1 65038 INPPL1
neurotrophic tyrosine kinase, receptor, type 3 29613 NTRK3
mannoside acetyl glucosaminyltransferase 3 29582 MGAT3
interleukin 7 25647 IL7
Cell cycle
interleukin 7 25647 IL7
myogenic differentiation 1 337868 MYOD1
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
calcitonin receptor 116506 CALCR
structure-specific recognition protein 1 81785 SSRP1
midkine 81517 MDK
chemokine (C–C motif ) ligand 3 25542 CCL3
signal transducer and activator of transcription 5A 24918 STAT5A
Fanconi anemia, complementation group C 24361 FANCC
androgen receptor 24208 AR
Cell death
interleukin 7 25647 IL7
myogenic differentiation 1 337868 MYOD1
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
calcitonin receptor 116506 CALCR
structure-specific recognition protein 1 81785 SSRP1
midkine 81517 MDK
chemokine (C–C motif ) ligand 3 25542 CCL3
signal transducer and activator of transcription 5A 24918 STAT5A
Fanconi anemia, complementation group C 24361 FANCC
androgen receptor 24208 AR
protein kinase, AMP-activated, alpha 2
catalytic subunit
78975 PRKAA2
neurotrophic tyrosine kinase, receptor, type 3 29613 NTRK3
mannoside acetyl glucosaminyltransferase 3 29582 MGAT3
metallothionein 3 117038 MT3
HLA-B–associated transcript 3 94342 BAT3
nuclear receptor subfamily 2, group F, member 1 81808 NR2F1
linker for activation of T cells 81511 LAT
epithelial membrane protein 3 81505 EMP3
thioredoxin reductase 2 50551 PAX3
xanthine dehydrogenase 29289 XDH
arrestin, beta 2 25388 ARRB2
milk fat globule–EGF factor 8 protein 25277 MFGE8
early growth response 4 25129 EGR4
transthyretin 24856 TTR
myosin heavy chain 11 24582 MYH11
metallothionein 1a 24567 MT1E
benzodiazepine receptor, peripheral 24230 TSPO
Cell morphology
myogenic differentiation 1 337868 MYOD1
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
chemokine (C–C motif ) ligand 3 25542 CCL3
mannoside acetyl glucosaminyltransferase 3 29582 MGAT3
nuclear receptor subfamily 2, group F, member 1 81808 NR2F1
thioredoxin reductase 2 50551 PAX3
myosin heavy chain 11 24582 MYH11
potassium inwardly rectifying channel,
subfamily J, member 11
83535 KCNJ11
lumican 81682 LUM
neuropilin 2 81527 NRP2
high mobility group box transcription factor 1 27080 HBP1
persephin 25525 PSPN
Cell signaling
linker for activation of T cells 81511 LAT
arrestin, beta 2 25388 ARRB2
Cell to cell signaling and interaction
linker for activation of T cells 81511 LAT
arrestin, beta 2 25388 ARRB2
chemokine (C–C motif ) ligand 3 25542 CCL3
thioredoxin reductase 2 50551 PAX3
Gene Names Locus ID Symbol
neuropilin 2 81527 NRP2
interleukin 7 25647 IL7
midkine 81517 MDK
signal transducer and activator of transcription 5A 24918 STAT5A
Fanconi anemia, complementation group C 24361 FANCC
xanthine dehydrogenase 29289 XDH
milk fat globule–EGF factor 8 protein 25277 MFGE8
inositol polyphosphate phosphatase–like 1 65038 INPPL1
pleckstrin homology, Sec7 and coiled/coil
domains 1
116691 PSCD1
a disintegrin and metalloproteinase
domain 15 (metargidin)
57025 ADAM15
Cellular assembly and organization
neuropilin 2 81527 NRP2
signal transducer and activator of transcription 5A 24918 STAT5A
xanthine dehydrogenase 29289 XDH
milk fat globule–EGF factor 8 protein 25277 MFGE8
inositol polyphosphate phosphatase–like 1 65038 INPPL1
nuclear receptor subfamily 2, group F, member 1 81808 NR2F1
myosin heavy chain 11 24582 MYH11
lumican 81682 LUM
androgen receptor 24208 AR
neurotrophic tyrosine kinase, receptor, type 3 29613 NTRK3
metallothionein 1a 24567 MT1E
Cellular compromise
xanthine dehydrogenase 29289 XDH
neurotrophic tyrosine kinase, receptor, type 3 29613 NTRK3
metallothionein 1a 24567 MT1E
linker for activation of T cells 81511 LAT
chemokine (C–C motif ) ligand 3 25542 CCL3
thioredoxin reductase 2 50551 PAX3
metallothionein 3 117038 MT3
early growth response 4 25129 EGR4
Cellular development
xanthine dehydrogenase 29289 XDH
neurotrophic tyrosine kinase, receptor, type 3 29613 NTRK3
linker for activation of T cells 81511 LAT
chemokine (C–C motif ) ligand 3 25542 CCL3
thioredoxin reductase 2 50551 PAX3
neuropilin 2 81527 NRP2
signal transducer and activator of transcription 5A 24918 STAT5A
nuclear receptor subfamily 2, group F, member 1 81808 NR2F1
myosin heavy chain 11 24582 MYH11
androgen receptor 24208 AR
arrestin, beta 2 25388 ARRB2
interleukin 7 25647 IL7
Fanconi anemia, complementation group C 24361 FANCC
myogenic differentiation 1 337868 MYOD1
high mobility group box transcription factor 1 27080 HBP1
calcitonin receptor 116506 CALCR
interferon-induced transmembrane
protein 2 (1–8D)
114709 IFITM2
CD164 antigen 83689 CD164
etoile, Sam68-like protein SLM-2 64015 KHDRBS3
carbonic anhydrase 2 54231 CA2
testis-specific protein, Y-linked 25223 TSPY1
histone 1, H1t 24438 HIST1H1T
Cellular function and maintenance
linker for activation of T cells 81511 LAT
chemokine (C–C motif ) ligand 3 25542 CCL3
signal transducer and activator of transcription 5A 24918 STAT5A
nuclear receptor subfamily 2, group F, member 1 81808 NR2F1
androgen receptor 24208 AR
interleukin 7 25647 IL7
Fanconi anemia, complementation group C 24361 FANCC
myogenic differentiation 1 337868 MYOD1
high mobility group box transcription factor 1 27080 HBP1
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
Cellular growth and proliferation
chemokine (C–C motif ) ligand 3 25542 CCL3
signal transducer and activator of transcription 5A 24918 STAT5A
androgen receptor 24208 AR
interleukin 7 25647 IL7
Fanconi anemia, complementation group C 24361 FANCC
Table W5. (continued )
Gene Names Locus ID Symbol
myogenic differentiation 1 337868 MYOD1
casein kinase II, alpha 1 polypeptide 116549 CSNK2A1
xanthine dehydrogenase 29289 XDH
neurotrophic tyrosine kinase, receptor,
type 3
29613 NTRK3
thioredoxin reductase 2 50551 PAX3
myosin heavy chain 11 24582 MYH11
arrestin, beta 2 25388 ARRB2
calcitonin receptor 116506 CALCR
CD164 antigen 83689 CD164
testis-specific protein, Y-linked 25223 TSPY1
metallothionein 1a 24567 MT1E
metallothionein 3 117038 MT3
early growth response 4 25129 EGR4
lumican 81682 LUM
midkine 81517 MDK
a disintegrin and metalloproteinase
domain 15 (metargidin)
57025 ADAM15
mannoside acetyl glucosaminyltransferase 3 29582 MGAT3
epithelial membrane protein 3 81505 EMP3
nucleosome assembly protein 1–like 1 89825 NAP1L1
solute carrier family 29 (nucleoside transporters),
member 1
63997 SLC29A1
beta-microseminoprotein 29311 MSMB
ferritin light chain 1 29292 FTL
Cellular movement
chemokine (C–C motif ) ligand 3 25542 CCL3
androgen receptor 24208 AR
interleukin 7 25647 IL7
xanthine dehydrogenase 29289 XDH
thioredoxin reductase 2 50551 PAX3
myosin heavy chain 11 24582 MYH11
arrestin, beta 2 25388 ARRB2
neuropilin 2 81527 NRP2
DNA replication, recombination, and repair
androgen receptor 24208 AR
arrestin, beta 2 25388 ARRB2
structure-specific recognition protein 1 81785 SSRP1
phosphodiesterase 5A, cGMP-specific 171115 PDE5A
Drug metabolism
androgen receptor 24208 AR
xanthine dehydrogenase 29289 XDH
solute carrier family 29 (nucleoside transporters),
member 1
63997 SLC29A1
solute carrier family 28 (sodium-coupled nucleoside
transporter), member 2
60423 SLC28A2
Free radical scavenging
xanthine dehydrogenase 29289 XDH
Fanconi anemia, complementation group C 24361 FANCC
Gene expression
Fanconi anemia, complementation group C 24361 FANCC
androgen receptor 24208 AR
structure-specific recognition protein 1 81785 SSRP1
interleukin 7 25647 IL7
myosin heavy chain 11 24582 MYH11
signal transducer and activator of transcription 5A 24918 STAT5A
myogenic differentiation 1 337868 MYOD1
nuclear receptor subfamily 2, group F, member 1 81808 NR2F1
Lipid metabolism
androgen receptor 24208 AR
signal transducer and activator of transcription 5A 24918 STAT5A
xanthine dehydrogenase 29289 XDH
mannoside acetyl glucosaminyltransferase 3 29582 MGAT3
inositol polyphosphate phosphatase–like 1 65038 INPPL1
protein kinase, AMP-activated, alpha 2
catalytic subunit
78975 PRKAA2
nuclear receptor binding factor 1 29470 MECR
selenoprotein P, plasma, 1 29360 SEPP1
Molecular transport
androgen receptor 24208 AR
signal transducer and activator of transcription 5A 24918 STAT5A
xanthine dehydrogenase 29289 XDH
mannoside acetyl glucosaminyltransferase 3 29582 MGAT3
Table W5. (continued )
Gene Names Locus ID Symbol
protein kinase, AMP-activated, alpha 2
catalytic subunit
78975 PRKAA2
Fanconi anemia, complementation group C 24361 FANCC
interleukin 7 25647 IL7
solute carrier family 29 (nucleoside transporters),
member 1
63997 SLC29A1
solute carrier family 28 (sodium-coupled
nucleoside transporter), member 2
60423 SLC28A2
neurotrophic tyrosine kinase, receptor, type 3 29613 NTRK3
carbonic anhydrase 2 54231 CA2
potassium inwardly rectifying channel, subfamily J,
member 11
83535 KCNJ11
solute carrier family 5 (sodium-dependent
vitamin transporter), member 6
170551 SLC5A6
solute carrier family 32 (GABA vesicular
transporter), member 1
83612 SLC32A1
solute carrier family 30 (zinc transporter),
member 2
25362 SLC30A2
sodium channel, nonvoltage-gated, type I,
alpha polypeptide
25122 SCNN1A
Nucleic acid metabolism
xanthine dehydrogenase 29289 XDH
solute carrier family 29 (nucleoside transporters),
member 1
63997 SLC29A1
solute carrier family 28 (sodium-coupled
nucleoside transporter), member 2
60423 SLC28A2
nuclear receptor binding factor 1 29470 MECR
arrestin, beta 2 25388 ARRB2
phosphodiesterase 5A, cGMP-specific 171115 PDE5A
Post–translational modification
xanthine dehydrogenase 29289 XDH
RNA post–transcriptional modification
Fanconi anemia, complementation group C 24361 FANCC
Small molecule biochemistry
xanthine dehydrogenase 29289 XDH
solute carrier family 29 (nucleoside transporters),
member 1
63997 SLC29A1
solute carrier family 28 (sodium-coupled
nucleoside transporter), member 2
60423 SLC28A2
nuclear receptor binding factor 1 29470 MECR
arrestin, beta 2 25388 ARRB2
phosphodiesterase 5A, cGMP-specific 171115 PDE5A
androgen receptor 24208 AR
signal transducer and activator of transcription 5A 24918 STAT5A
mannoside acetyl glucosaminyltransferase 3 29582 MGAT3
protein kinase, AMP-activated, alpha 2
catalytic subunit
78975 PRKAA2
interleukin 7 25647 IL7
neurotrophic tyrosine kinase, receptor, type 3 29613 NTRK3
carbonic anhydrase 2 54231 CA2
solute carrier family 5 (sodium-dependent
vitamin transporter), member 6
170551 SLC5A6
solute carrier family 32 (GABA vesicular
transporter), member 1
83612 SLC32A1
inositol polyphosphate phosphatase–like 1 65038 INPPL1
selenoprotein P, plasma, 1 29360 SEPP1
metallothionein 1a 24567 MT1E
metallothionein 3 117038 MT3
ferritin light chain 1 29292 FTL
Vitamin and mineral metabolism
solute carrier family 5 (sodium-dependent
vitamin transporter), member 6
170551 SLC5A6
linker for activation of T cells 81511 LAT
Others/unclassified
guanine nucleotide binding protein (G protein),
gamma 8 subunit
245986 GNG8
H1 histone family, member 4 201097 H1F4
glutaminase 2 (liver, mitochondrial) 192268 GLS2
seminal vesicle secretion 3 192239 SEMG2
proteasome (prosome, macropain) 26S subunit,
non-ATPase, 9
161475 PSMD9
protein tyrosine phosphatase, nonreceptor type 23 117552 PTPN23
CD52 antigen 117054 CD52
Table W5. (continued )
Gene Names Locus ID Symbol
ribosomal protein L6 117042 RPL6
importin 13 116458 IPO13
general transcription factor IIa 2 83828 GTF2A2
tripartite motif protein 3 83616 TRIM3
ribosomal protein L5 81763 RPL5
ribosomal protein S8 65136 RPS8
defensin beta 3 64389 DEFB4
ribosomal protein L31 64298 RPL31
ribosomal protein L35a 57809 RPL35A
solute carrier family 14 (urea transporter), member 1 54301 SLC14A1
probasin 54193 PBSN
mini chromosome maintenance-deficient 6
(S. cerevisiae)
29685 MCM6
proteasome (prosome, macropain) subunit,
beta type 3
29676 PSMB3
peptidyl arginine deiminase, type II 29511 PADI2
coronin, actin-binding protein, 1B 29474 CORO1B
ribosomal protein S26 27139 RPS26
sialyltransferase 8 C 25547 ST8SIA3
crystallin, beta B2 25422 CRYBB2
glutamate-ammonia ligase (glutamine synthase) 24957 CCDC92
malate dehydrogenase 1, NAD (soluble) 24551 MDH1
Genes were categorized according to their cellular functions (in bold and italics).
Table W5. (continued )
